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Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and 
mortality worldwide and is a risk factor for lung cancer development. COPD 
encompasses both emphysema and chronic bronchitis, the pathogenesis of which are 
unclear. In this dissertation, I leveraged genome-wide gene-expression studies of 
emphysema and lung cancer to investigate pathogenesis and carcinogenesis in COPD.  
 
Tobacco smoke is the primary cause of emphysema. The most severe form is also 
associated with alpha1-antitrypsin deficiency (AATD) resulting from a mutation. In this 
study, I leveraged multiple lung samples from patients with emphysema, with or without 
AATD. While genes involved in tissue repair decreased with emphysema severity, the 
unfolded protein response (UPR) was uniquely changed in AATD lungs. AATD may 
play multiple roles in emphysema and UPR activation suggests AAT replacement therapy 
may be insufficient to treat this form of emphysema. 
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Emphysema is a progressive disease, and the mean linear intercept (Lm) can serve as a 
surrogate of progression. I evaluated whether Lm increases in non-diseased lungs may 
represent similar processes to those occurring in emphysema, and could offer insight into 
early stages of disease or homeostasis. Genes involved in tissue repair increased with Lm 
in controls but decreased in disease. Tissue repair processes may be active in even the 
non-insulted lung, suggesting their activity is necessary for lung homeostasis and their 
deficiency may drive emphysema progression. 
 
Finally, COPD patients are at increased lung cancer risk, and transcriptomic changes 
common to both diseases could explain this risk. In both COPD and lung cancer, I 
discovered that H3K27Me3 regulated genes are repressed, and that the methyltransferase 
responsible for H3K27me3, EZH2, is induced. H3K27Me3, an oncogenic histone 
modification, may drive carcinogenesis and pathogenesis in COPD. 
 
Though usual and AATD emphysema share transcriptomic signatures associated with 
tissue repair, which may be active in the normal homeostatic lung, the UPR changes in 
AATD emphysema only; successful therapeutic strategies in emphysema will need to 
account for this difference. In COPD, H3K27Me3 may play a role in both pathogenesis 
and carcinogenesis, making it an attractive target for therapeutic interventions, but one 
that would need further augmentation in AATD.  
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Chapter One: Introduction 
Public health burden of COPD and lung cancer 
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and 
mortality in the United States and throughout the world. It is debilitating for patients and 
costly to the health care system and the economy. While it was the fifth most common 
cause of death in 1980, the Centers for Disease Control reported that COPD was the third 
most common cause of death in the U.S in 2014 [1]. In 2012, the total cost of COPD was 
estimated to be $68 billion, including $54 billion in health care expenditures and $14 
billion in lost productivity. Approximately 15 million people are diagnosed with COPD 
(6.4% of the U.S. population) and an estimated 12 million people have COPD but are 
undiagnosed [2]. These individuals are more likely to be unable to work, to have an 
activity limitation, and to have difficulty walking or climbing stairs [3]. Patients with 
COPD are also more likely to develop lung cancer [4-9]. Lung cancer is the malignancy 
responsible for the most cancer related deaths and has a five-year survival rate of only 
18.7% [10].  
 
Just over 50 years ago, in 1964, the Surgeon General released the first report on the 
deleterious health effects of smoking and tobacco use. Education efforts regarding the 
effects of tobacco use have decreased smoking rates in the United States to their lowest in 
recent history, but rates differ based on socioeconomic status. More than 30% of people 
below the poverty line regularly smoke, while that rate drops to about 20% for those 
above the line [11]. Decreasing domestic smoking rates have decreased overall incidence 
		 2 
of tobacco related illness, but smoking rates and the incidence of tobacco related illnesses 
are increasing worldwide. Fifty percent of young men and 10% of young women are 
smoking throughout the world. Approximately 100 million deaths were caused by 
tobacco in the 20th century and if current smoking rates continue, almost one billion 
deaths will be tobacco-attributable in this century, mostly in low- and middle-income 
countries [12]. Furthermore, the research funding rate for these tobacco related diseases is 
incommensurate with the significant health impact on patients, the health care related 
costs, and their overall economic and societal impact [13].  
 
Chronic obstructive pulmonary disease 
The main risk factor for COPD is smoking, but only 25% of smokers will develop 
COPD, suggesting the accounting for interaction between exposure and genetics will be 
critical for understanding disease pathogenesis [14]. Most patients with COPD are current 
or former smokers and are not diagnosed until at least age 40, indicating cumulative 
exposure increases the risk of disease development. The common symptoms of COPD 
include chronic cough, increased sputum production, anorexia, weight loss, fatigue, and 
dyspnea. The COPD phenotype is defined by decreased lung function as measured by 
pulmonary function tests (PFTs), which quantify the degree of lung function and are used 
for diagnosing and monitoring COPD over time. COPD is staged according to the 
severity of lung function decline based on advice laid out by the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) [15]. Symptom severity varies greatly 
between patients due to the nature of the underlying lung damage, which is caused by a 
		 3 
combination of emphysematous destruction and chronic bronchitis. Both of these 
processes lead to lung obstruction, but do so through different mechanisms. Emphysema 
manifests as the destruction of the alveolar sacs and septal walls, as well as a decrease in 
the elasticity and structural integrity of the lungs. The surface area for gas exchange is 
limited by alveolar destruction and the lung collapses more readily with decreasing 
elasticity, leading to air trapping. Chronic bronchitis, on the other hand, manifests as 
increased sputum production and inflammatory infiltration of the airways, which lead to a 
decrease in airway size. Once these pathologies are initiated, they inexorably and 
irreversibly progress. The treatments that exist for COPD are not disease modifying, but 
rather are symptom managing. Patients are commonly given bronchodilators and inhaled 
corticosteroids to relax the muscles surrounding the airway and decrease bronchial 
inflammation, respectively. These treatments help with day-to-day management of COPD 
but offer no long-term benefit [16]. There are currently no cures for COPD, which 
explains why it was the third most common cause of death in the U.S. in 2014 [1].  
 
Emphysema and alpha1-antitrypsin deficiency 
Emphysema is one component of COPD and normally develops between 45 and 60 years 
of age. The exact molecular mechanisms underlying emphysema pathogenesis are not 
well understood, but a role for an imbalance between the proteinases and anti-proteinases 
of the lung is well accepted. Though smoking remains the primary risk factor for the 
development of emphysema, inherited mutations in the SERPINA1 gene, which codes for 
alpha1-antitrypsin (AAT), leads to AAT deficiency (AATD) and is associated with a 
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severe and early onset form of emphysema and liver disease. Functional alpha1-
antitrypsin normally inhibits neutrophil elastase (NE), a potent serine proteinase released 
by activated neutrophils that can degrade the extracellular matrix of the lung. Inherited 
mutations in the SERPINA1 gene can lead to AAT misfolding, inactivity, and deficiency. 
The majority of functional AAT is normally produced and secreted by the liver into the 
circulation, through which it travels to the lung to protect it from excessive degradation 
by NE. The prevailing theory of AATD-associated emphysema pathogenesis is that the 
lack of functional AAT allows neutrophil elastase released from tobacco-activated and 
recruited neutrophils to excessively degrade the lung’s extracellular matrix, from which 
recovery becomes impossible, and emphysema ensues. Liver disease, including 
hepatocellular carcinoma and cirrhosis is also common in AATD, and likely develops 
from the accumulation of misfolded AAT in the hepatocytes. This inherited disease is 
estimated to affect 1 in 3000 to 5000 people in the United States [17, 18] and up to 5% of 
COPD patients [19, 20], which means it is a driver of significant morbidity and mortality.  
 
Several cross-sectional studies have identified pathways changed between the lungs of 
patients with and without COPD [21-24], often with little overlap. A few studies have 
examined specifically the emphysema portion of COPD [25-28]. One of these studies has 
examined the potential transcriptomic effects of AATD in emphysema and found that 
“usual” and AATD-associated emphysema mostly shared molecular profiles [25]. The 
most granular molecular study to date examined gene expression signatures of 
emphysema severity using repeated measures from within the same lungs [28], which 
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facilitated the discovery of glycyl-L-histidyl-L-lysine (GHK) as a potential treatment for 
emphysema. No study to date has identified transcriptomic level information to help 
explain the more severe emphysema phenotype observed in AATD patients. 
  
Lung cancer 
The link between smoking and lung cancer is well documented, with at least eight out of 
ten lung cancer deaths linked to smoking [29]. Lung cancer risk is increased in former 
smokers up to 30 years after smoking cessation [30]. Symptoms are similar to COPD and 
include chronic cough, weight loss, dyspnea, and fatigue, and can include hemoptysis 
(i.e. coughing up blood). Like COPD, lung cancer, once initiated, is difficult to curtail. 
Lung cancer is responsible for the most cancer deaths annually even though it is not the 
most prevalent, and the five year survival has improved only from 12% to 19% since the 
1970s [10]. Usually, symptoms of lung cancer do not occur until the disease has reached 
an advanced stage, which make it harder to treat and leads to high mortality rates. This is 
complicated by the fact that COPD increases lung cancer risk and that the symptoms of 
COPD and lung cancer are similar. While patients diagnosed with stage I cancer have a 
50% five-year survival rate, patients with stage IV disease have a 1% five-year survival 
rate [29].  
 
COPD increases lung cancer risk 
In 1986 one study found that while controlling for age, sex, occupation, and smoking 
history, COPD patients had an increased rate of lung cancer development [4]. Because of 
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the strong shared etiological link to tobacco, matching for smoking history was critically 
important for this study, and suggested for the first time that COPD increased lung cancer 
risk, regardless of smoking history. Several groups have affirmed the association between 
COPD and increased lung cancer risk [6-8, 31]. One meta-analysis of 39 studies 
calculated that the combined relative risk of lung cancer in COPD was 1.83 [32]. In fact, 
tumors in the lungs of patients with COPD were more likely to originate in regions of 
severe emphysema [33]. Furthermore, AATD, also carries an increased lung cancer risk 
[34-36], suggesting that regardless of the underlying etiology, emphysema increases lung 
cancer risk. Authors of one of the largest studies to date suggested that smoking habit and 
the timing of COPD diagnosis, rather than the presence of the disease, could account for 
the observed increased incidence of lung cancer among COPD patients. When correcting 
for smoking and including only patients with a 10 year or greater history of COPD, 
however, this study still found that the odds of lung cancer development was greater 
among the COPD population (odds ratio: 2.18) [5]. The mechanisms that increase lung 
cancer incidence in COPD are unclear. 
 
 
Specific Aims 
Aim 1: Compare and contrast gene expression effects in emphysematous lungs with or 
without alpha1-antitrypsin deficiency  
Emphysema is a disease process characterized by unchecked, progressive, and 
irreversible destruction of functional lung tissue. Smoking is the primary risk factor for 
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emphysema, but alpha1-antitrypsin deficiency is the most important inherited disorder 
associated with emphysema. Approximately 5% of COPD patients are diagnosed with 
AATD, but this is thought to underrepresent the actual prevalence of disease. Patients 
with AATD present with severe emphysema at an early age, and though this AATD-
associated emphysema is thought to result from alpha1-antitrypsin deficiency, which 
allows the potent proteinase, neutrophil elastase, to destroy the lung unchecked, only one 
group has examined the genome wide implications of AATD in the lung. The goal of this 
study is to identify transcriptomic similarities and differences between emphysematous 
lungs with or without AATD, by comparing “usual” and AATD-associated emphysema, 
by identifying gene expression profiles associated with emphysema severity across both 
of these primary forms of emphysema, and by identifying profiles associated with disease 
severity differently between the two groups. 	
Aim 2: Compare and contrast gene expression signatures of healthy alveolar spacing and 
emphysematous destruction 
Though COPD is the most common form of smoking associated disease, only 
approximately 25% of smokers will ever develop the disease, suggesting a strong 
underlying genetic component to disease, that might manifest in differences measurable 
at the gene expression level.  In fact, the estimated heritability of lung function and 
COPD is 37%, according to one study [37]. Many groups have already characterized the 
cross-sectional gene expression differences between healthy smokers and smokers with 
COPD, but no groups have explored the transcriptome as it relates to healthy alveolar 
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spacing. The goal of this study is to identify the genes and processes that change in the 
healthy lung with alveolar spacing and to compare these changes to those occurring with 
emphysema severity in diseased lungs. These changes could provide insight into early 
stages of emphysema or the lung homeostasis program and its relationship with disease.  	
Aim 3: Connect the COPD lung and lung cancer transcriptomes 
COPD is the most prevalent smoking associated disease. Lung cancer, also a common 
smoking associated disease, is responsible for the most malignancy related deaths. 
Unfortunately, the presence of COPD has been demonstrated time and again to increase 
the incidence of lung cancer, independent of smoking history, suggesting COPD and lung 
cancer share a common disease process or alternatively, that the pathogenic processes of 
COPD drive carcinogenesis. Though several groups have reviewed potential mechanistic 
links between these two disease states, no study to date has explored the possibility that a 
transcriptomic connection may link these diseases at the molecular level. The goal of this 
study is to examine the transcriptomic effects of COPD and lung cancer and to identify 
any overlapping processes or molecular events that help explain the increased lung cancer 
risk observed in the COPD population.  
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Chapter Two: Data acquisition, processing, and profiling 
Purpose 
In chapters three and four I investigate gene expression changes associated with 
emphysema severity and alveolar spacing (i.e. the mean linear intercept, Lm) across 15 
lungs collected as part of one study. These lungs were collected, processed, and profiled 
by our collaborators at the University of British Columbia (UBC) in the laboratory of 
James Hogg, M.D., Ph.D. Our laboratory received tissue samples stored in qiazol from 
UBC, and Gang Liu, Ph.D. and his team, isolated RNA from these samples so that the 
BU microarray core could hybridize them onto microarrays, scan the arrays, and generate 
CEL files, which I received. I then was able to normalize the CEL files and generate 
quality control metrics. The purpose of this brief chapter is to provide details regarding 
the methodologies utilized by our collaborators and the members of our lab that were 
necessary so that I could perform the various gene expression analyses, which are 
detailed in chapters three and four.  
 
Materials and Methods 
Sample acquisition and processing 
Ten emphysematous lungs were collected by our collaborators at UBC after being 
explanted from patients with GOLD stage IV COPD, with or without alpha1-antitrypsin 
deficiency. Five control lungs were collected from non-emphysematous donors after they 
were released for research because no suitable match could be found for the lungs. All 15 
lungs were inflated, frozen, and subsequently sliced at 2 cm intervals in the transverse 
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plane into eight slices.  Two adjacent cores were taken from these slices. One core was 
processed on the microCT by Dragos Vasilescu, Ph.D. (UBC) to measure the mean linear 
intercept (Lm). The second core was processed by Daisuke Kinose, Ph.D. (UBC), by 
laser capture microdissection (LCM) to separate airway walls from parenchymal tissue.  
 
Tissue laser capture microdissection (LCM) 
Daisuke Kinose, Ph.D., of UBC, used hematoxylin and eosin stained sections to find 
airways. His definition of airway was that of a structure with airway epithelial cells. Most 
of the airway sections contained multiple airway structures, likely at different airway 
generations. He tried not to include airways with cartilage in an attempt to isolate airway 
generations from around the terminal bronchioles and respiratory bronchioles. He 
collected whole airway walls using LCM, so airway samples consisted of airway 
epithelial cells, smooth muscle cells, fibroblasts, inflammatory cells if they were there, 
and endothelial cells.  Parenchymal tissue was all that remained after airway wall 
removal, and included alveolar tissue (type 1 and 2 epithelial cells), vessels (endothelial 
cells, smooth muscle cells), inflammatory cells, and fibroblasts. 
 
Measurement of mean linear intercept (Lm) 
Emphysema severity, or alveolar spacing in the case of non-emphysematous lungs, was 
measured by Dragos Vasilescu Ph.D. He calculated the mean linear intercept (Lm), as 
previously described [28]. 
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Microarray sample processing and quality control 
Gang Liu, Ph.D. and members of our lab isolated high molecular weight (HMW; mRNA- 
containing fraction) RNA from LCM tissue cores using the miRNeasy Mini Kit (Qiagen). 
The RNA integrity was assessed using an Agilent 2100 Bioanalyzer and RNA purity was 
assessed using a NanoDrop spectrophotometer. One ug of RNA was processed and 
hybridized onto the Human Exon 1.0 ST array (Affymetrix Inc.) by the BU microarray 
core, according to the manufacturer’s protocol as previously described. Members of the 
core then scanned the arrays to generate CEL files. 
 
I used the robust multi array normalization algorithm [38] and BrainArray V17 CDF to 
generate log2 normalized gene expression data that could be used within the R 
environment for statistical analysis. I used the RLE and NUSE algorithms [39] to test 
array quality and identify any abnormal or low quality arrays. Normalization was 
completed and quality control metrics were generated using R v 2.1.15.  
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Chapter Three: Gene expression signatures of lung tissue destruction in “usual” 
emphysema and alpha1-antitrypsin deficiency associated emphysema 
Abstract 
I identified a number of genes whose expression changed with increasing emphysema 
severity regardless of the alpha1-antitrypsin deficiency (AATD) status of the originating 
lungs. The majority of identified genes decreased with disease severity and were enriched 
with genes involved in various aspects of lung repair. Among the genes that increased 
with severity was Surfactant protein D (SFTPD), which has been demonstrated to be a 
biomarker of COPD and lung damage [40-43], as well as a tag for apoptotic cells, 
marking them for immune cell mediated phagocytosis [44]. Interestingly, I identified a 
set of genes that changed with increasing emphysema severity uniquely among the lungs 
with AATD. These genes were associated with the endoplasmic reticulum (ER) 
membrane, ER associated degradation (ERAD), and the unfolded protein response 
(UPR). Genes induced along all three arms of the UPR were enriched with genes that 
increased with emphysema severity specifically in the AATD lungs. I have provided 
evidence that AATD is associated with changes to the UPR that may drive AATD-
emphysema. 
 
Background 
Chronic obstructive pulmonary disease (COPD) is a serious public health burden 
characterized by a combination of chronic bronchitis and emphysema. At least 25% of 
cigarette smokers go on to develop COPD [14], but smoking is only one of a few risk 
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factors for the disease. In addition to smoking, inherited mutations in the SERPINA1 
gene have also been linked to the development of COPD, specifically through the 
development of alpha1-antitrypsin deficiency (AATD). This inherited disease has an 
estimated prevalence of 1 case per 3000 to 5000 people in the United States [17, 18] and 
up to 5% of COPD patients are thought to have AATD [19, 20]. Alpha1-antitrypsin 
(AAT) – the protein coded for by the gene SERPINA1 – normally inhibits neutrophil 
elastase (NE) and its deficiency leads to early onset and severe emphysema and liver 
disease. There are several SERPINA1 mutations associated with AATD, but the Z 
mutation, in which the glutamic acid at position 342 is replaced with a lysine (the 
resulting protein is referred to as ZAAT), is the most clinically relevant as it leads to 
severe disease. As much as 95% of the AATD population has at least one Z allele [45, 
46]. The Z mutation leads not only to a loss of the functional protein, but also leads to a 
gain-of-toxic function. The ZAAT protein cannot properly fold, polymerizes, and 
accumulates in globules in the endoplasmic reticulum (ER) in some types of AAT 
secreting cells. In the liver, the accumulation of abnormally folded ZAAT causes 
cirrhosis and hepatocellular carcinoma [47, 48]. However, in the lung, exactly which cells 
secrete ZAAT and the potential implications of its accumulation remain less well 
understood.  
 
The traditional paradigm of disease pathogenesis in AATD implicates an imbalance 
between proteinases (released from neutrophils) and anti-proteinases, resulting in 
emphysema. ZAAT polymerization and retention in the liver decreases circulating AAT, 
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and insufficient functional AAT allows neutrophil elastase to destroy healthy, functional 
tissue in the lung. However, recent studies have shown that AAT is produced in the lung 
at least by bronchial epithelial cells [49-51], if not also by alveolar cells [52], suggesting 
the possibility that AATD-related emphysema does not result from liver dysfunction 
alone; the lung may play a role in its own destruction. Moreover, the ZAAT protein acts 
as a powerful neutrophil chemoattractant, suggesting its role in emphysema pathogenesis 
is multifaceted [49], as neutrophils are increased in the lungs of AATD patients [53]. 
Lastly, the ZAAT protein accumulates within the ER of hepatocytes and has been 
demonstrated to cause protein immobility [54], sensitizing these cells to secondary 
sources of ER stress, which leads to increased rates of apoptosis. What relevance this 
finding in particular has in the lungs has not yet been evaluated. 
 
Several groups have profiled the transcriptional changes associated with COPD or 
emphysema cross-sectionally, relying mostly on pulmonary function tests (PFTs) to 
dichotomize their patient samples [21, 25, 26, 55-58]. Only one study to date has 
examined the transcriptomic effects in the lung associated with alpha1-antitrypsin 
deficiency related emphysema. Golpon and colleagues [25] showed that gene expression 
profiles are mostly shared between “usual” emphysema and AATD-related emphysema. 
Our group has previously improved on the methodology of these cross-sectional studies 
in order to gain insights into the mechanisms of emphysema progression within a patient. 
In six lungs from patients with COPD (1 with AATD) and two donor lungs, our lab 
captured paired cores from regularly spaced regions from the apex to the base of 
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explanted lungs, profiled gene expression from one core, and measured the mean linear 
intercept with microCT in the other. In this way, Campbell and colleagues were able to 
identify a decrease in activity of the TGFb signaling pathway with increasing emphysema 
severity and identify GHK as a potential disease modifying agent in emphysema that acts 
on the TGFb pathway [28]. 
 
In the present study our collaborators have further improved this paradigm by laser 
capture microdissecting (LCM) whole airway walls away from the functional 
parenchymal tissue, which has enabled us to profile gene expression in both tissue 
compartments separately. Furthermore, we have included 5 SERPINA1-MM normal 
lungs with centrilobular emphysema (CLE) and 5 SERPINA1-ZZ lungs with panlobular 
emphysema (PLE), enabling a more detailed examination of gene expression changes 
associated with the AATD-associated emphysema subtype.  
 
I identified a number of genes whose expression changed with increasing emphysema 
severity regardless of the SERPINA1 mutation status of the originating lungs. The 
majority of identified genes decreased with emphysema severity and were enriched with 
genes involved in lung repair. Though I did not identify any genes differentially 
expressed between emphysema subtypes, I did identify a set of genes associated with the 
unfolded protein response (UPR) that increased with emphysema severity in AATD lungs 
only. Overall, “usual” and AATD emphysema share grossly similar gene expression 
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profiles, but importantly differ in that AATD emphysema is additionally associated with 
the UPR.  
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Materials and Methods 
Microarray gene expression data analysis strategy 
Statistical analysis was completed in a manner similar to Campbell’s publication [28]. In 
the expression data from the parenchymal tissue I utilized linear mixed effects (LME) 
modeling in conjunction with the likelihood ratio test (LRT) to identify differentially 
expressed genes associated with disease status (i.e. emphysematous tissue v control 
tissue) or emphysema severity (i.e. ln(Lm)). I undertook three separate analyses to 
identify (1) genes differentially expressed between emphysema subtypes, (2) genes 
changing with increasing emphysema severity across both subtypes, and (3) genes 
changing with emphysema severity differently between the emphysema subtypes. In each 
analysis, I attempted to identify a significant signature, compared the signature to 
previous studies, and performed biological enrichment analysis. In the analyses 
examining gene expression effects associated with Lm, I also tested whether the 
signatures changed concordantly with Lm after standardizing Lm within each patient 
lung to a mean of zero and standard deviation of one (Z-Score). This helps guard against 
outlier patients from disproportionately driving the makeup of the signature. For analysis 
2 I further tested the consistency of the signature by similarly standardizing Lm within 
each group, which guards against the Lm differences between the groups from driving the 
signature makeup. 
 
All statistical analysis was done in R v3.1.1. The R package nlme v3.1-128 was used for 
all LME modeling and nested LME models were compared by analysis of variance 
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(ANOVA) using LRT. Comparisons to external studies were done by gene set 
enrichment analysis, GSEA v2.2.3 [59]. Signatures were hierarchically clustered prior to 
biological enrichment analysis, which was done in Enrichr [60] with the search space 
limited to KEGG, Biocarta, Reactome, and gene ontology (GO) databases. 
 
Analysis 1. Gene expression differences between “usual” and AATD emphysema 
To identify genes differentially expressed between emphysema subtypes I generated two 
LME models and compared them by ANOVA: 
(1) Gene ~ slice + Lm + random(patient) + error 
(2) Gene ~ slice + Lm + group + random(patient) + error 
In these and the following equations, slice represents the height from which a sample was 
taken from within a lung, Lm represents emphysema severity – and we have used the 
natural log of Lm – and group represents the emphysema subtype of the sample. Note 
throughout this dissertation I refer to Lm to mean the natural log of Lm, for ease of 
reading.  
 
Analysis 2. Gene expression changes associated with emphysema severity 
I next sought to identify genes that change with emphysema severity consistently across 
both “usual” and AATD emphysema and used the two following equations, which I 
compared by ANOVA: 
(3) Gene ~ slice + group + random(patient) + error 
(4) Gene ~ slice + group + Lm + random(patient) + error 
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Analysis 3. Gene expression changes associated with emphysema severity, dependent on 
subtype 
Lastly, I wanted to identify any gene expression profiles that change with emphysema 
severity in an emphysema subtype-dependent manner and used the following equations, 
again compared by ANOVA: 
(5) Gene ~ slice + group + Lm + random(patient) + error 
(6) Gene ~ slice + group + Lm + group:Lm + random(patient) + error 
In this last set of equations, group:Lm represents the interaction between Lm and group.  
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Results 
Study Population 
Lm was measured using micro-CT scans taken from regularly spaced regions from within 
the lungs of ten patients with emphysema, five of whom also had AATD. As expected, 
the patients with AATD emphysema had a higher mean Lm than the patients with “usual” 
emphysema (Figure 1). Table 1 shows demographic, clinical, and genotype information 
for the ten lungs. The five lungs with AATD had panlobular emphysema (PLE) and were 
ZZ homozygotes for SERPINA1, while the five lungs without AATD had centrilobular 
emphysema (CLE) and were MM homozygotes (i.e. normal).  
  
Table 1. Demographic information for the 10 emphysema lungs. Patient	 Group	 Sex	 Age	 Pack	Years	 Smoker	 LM	Summary	 LM	Range	6970	 AATD	 M	 55	 6	 former	 1337	(604)	 494-2322	7026	 AATD	 M	 55	 9	 former	 1490	(696)	 780-2802	7031	 AATD	 M	 48	 25	 former	 1201	(167)	 955-1390	7034	 AATD	 M	 51	 25	 former	 1665	(466)	 901-2364	7263	 AATD	 F	 39	 18	 former	 1209	(132)	 1098-1498	6996	 CLE	 F	 77	 45	 former	 512	(176)	 340-903	7305	 CLE	 F	 58	 30	 former	 823	(99)	 715-967	7307	 CLE	 M	 55	 80	 former	 959	(718)	 475-2635	7336	 CLE	 F	 59	 40	 former	 572	(232)	 371-1102	7337	 CLE	 F	 53	 24	 former	 1397	(536)	 839-2363		
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No genes differentially expressed between emphysema subtypes 
Due to the unique presentation normally associated with AATD emphysema, I first 
sought to identify any gene expression differences between the two types of emphysema. 
I identified only 668 genes differentially expressed between emphysema subtypes 
(uncorrected p < 0.05), yet I would expect 985 genes to be differentially expressed at that 
p-value threshold by chance (data not shown). 
 
Figure 1. Distribution of natural log of Lm measurements by SERPINA1 mutation status. 
Each patient is represented by a different color and has up to 8 samples. The samples 
from the ZZ lungs have significantly higher values than the MM lungs (p < 0.0001). 
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 Pathways associated with regional emphysema severity independent of genotype 
The lack of gene expression differences between the two emphysema subtypes lead me to 
the hypothesis that the two subtypes are grossly similar, so I set out to expand on these 
similarities. Using linear mixed effects modeling, I identified 571 genes associated with 
Lm consistently across “usual” and AATD emphysema (q < 0.05) (Figure 2 panel A). 
Hierarchical clustering identified two clusters with 126 and 445 genes. The 126 genes 
were positively associated with Lm and the 445 genes were negatively associated with 
Lm. Using Enrichr [60], I found the positively associated genes were enriched with genes 
involved in eukaryotic translation elongation (q < 0.001), and also included Surfactant 
protein D (Figure 2 panel B), a known biomarker of lung damage [42], emphysema [41], 
and COPD [40]. The negatively associated genes were enriched with genes involved in 
axon guidance, focal adhesion, ECM and lamellipodium organization, angiogenesis, and 
the regulation of epithelial cell migration and of the actin cytoskeleton (q < 0.001). 
SRGAP2 is a gene involved in axon guidance and is provided as an exemplar gene that 
decreased with Lm (Figure 2 panel C). 
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Figure 2. Gene expression signature of regional emphysema severity independent of SERPINA1 status. (A) 
Supervised heat map of 571 genes (q < 0.05) associated with Lm. Samples (columns) are organized from 
mild to severe emphysema from left to right. Rows represent genes and are hierarchically clustered, 
resulting in two clusters of genes increasing or decreasing with disease severity. (B) Expression of SFTPD 
and (C) SRGAP2 are plotted against the natural log of Lm. The color of each dot represents the patient 
from which the sample was derived and the shape represents the SERPINA1 status of the patient (triangle 
= MM, circle = ZZ). 
(A)	
(B)	 (C)	
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To test whether samples with outlier Lm measurements disproportionately affected the 
makeup of this gene set, I standardized (Z-score normalized) the Lm measurements 
within each lung and repeated the same statistical analysis. I ranked all genes by the t-
statistic of the standardized Lm measurement and tested whether the 126-gene set and 
445-gene set were concordantly enriched, with GSEA. The 126 and 445 gene-sets were 
positively and negatively enriched, respectively (GSEA q < 0.001). I also wanted to 
demonstrate that the emphysema-severity associated genes were not identified due to 
group differences in Lm between MM and ZZ (AATD) lungs. To test this possibility, I 
standardized the Lm measurements within each group, ranked the genes by the t-statistic, 
and used GSEA to test for concordant enrichment. The 126 and 445 gene-sets were again 
concordantly enriched (GSEA q < 0.001) (Figure 3). 
Table 2. Enrichment results for genes decreasing with Lm consistently across 
“usual” and AATD emphysema. 
Category FDR q value 
Axon guidance (Homo sapiens) 1.47E-13 
Developmental Biology (Homo sapiens) 6.21E-11 
Focal adhesion (Homo sapiens) 3.21E-08 
Angiogenesis 1.23E-07 
Signal transduction (Homo sapiens) 1.31E-07 
Regulation of cell morphogenesis 1.44E-07 
Lamellipodium assembly 9.77E-07 
GTPase regulator activity 9.88E-07 
Extracellular matrix organization 1.18E-06 
Regulation of epithelial cell migration 7.61E-06 
Regulation of actin cytoskeleton (Homo 
sapiens) 2.35E-05 	
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Connection to previous gene expression signature of emphysema severity 
Campbell et al. previously published a 127-gene signature of emphysema severity in a 
cohort of eight lungs, six of which were from COPD patients (one with AATD), and two 
of which were from non-COPD donors [28]. Given the similarities between the two 
emphysema subtypes thus far presented, I wanted to test whether this previous signature 
Lm	standardized	within	each	lung	 Lm	standardized	within	each	group	
126-gene	set	increasing	with	Lm	
445-gene	set	decreasing	with	Lm	
Figure 3. Genes changing with Lm across “usual” and AATD emphysema are enriched after standardizing 
Lm measurements. In the left column, genes are ranked by the t-statistic of the Lm measurement 
standardized within each lung. In the right column, genes are ranked by the t-statistic of the Lm 
measurement standardized within each group. In the first row, the set of 126 genes that increase with Lm is 
positively enriched in both ranked lists (q < 0.001). In the second row, the set of 445 genes that decrease with 
Lm is negatively enriched in both ranked lists (q < 0.001). The red to blue color bar represents the ranked 
list of all genes, with red indicating a positive t-statistic and blue a negative t-statistic. Each black tick 
represents the location of one of the genes from the tested gene set. 
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was consistent in these ten new emphysema lungs and shared across both MM and ZZ 
lungs. I ranked genes by the t-statistic for Lm from equation (4), above, and tested the 
enrichment of the 127-gene signature, using GSEA. The signature was concordantly 
enriched in this new set of lungs (q < 0.001) (Figure 4).  
 
Pathways associated with regional emphysema severity dependent on genotype 
Thus far, I have characterized genomic similarities between the two emphysema 
subtypes, but the distinct clinical picture associated with AATD emphysema, that of a 
younger smoker with severe disease, begs the questions of whether there are gene 
expression alterations specific to AATD that could explain these differences. Using 
LME, I identified 616 genes associated with emphysema severity and dependent on 
genotype (i.e. the interaction effect) among MM and ZZ lungs (p < 0.01; 197 expected by 
chance). Hierarchical clustering identified three clusters of (1) 342, (2), 52, and (3) 222 
genes (Figure 5, panel A). None of the clusters was strongly associated with Lm in the 
MM lungs. In the ZZ lungs, however, cluster 1 decreased with Lm, while clusters 2 and 3 
Figure 4. The previously published 127- gene signature of emphysema severity 
is concordantly enriched in this new set of ten emphysematous lungs. The left 
panel shows the set of genes increasing with Lm from the 127-gene signature 
tested against the new lungs, and the right panel shows the set of genes 
decreasing with Lm. Both sets of genes were concordantly enriched (q < 0.001). 
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increased with Lm (Figure 5, panel B). Cluster 1 was enriched with genes involved in 
ATP binding, regulation of leukocyte degranulation, and regulation of GTPase activity (q 
< 0.05). Cluster 2 was enriched with genes involved in tissue homeostasis and multi-drug 
resistance, but each of these results depended on one gene each (q < 0.05). Cluster 3 was 
enriched with genes involved in the unfolded protein response (UPR) and protein export 
and processing, processes known to be disrupted in AATD (q < 0.05, Table 3).  
 
In order to demonstrate that the 616 identified genes were associated with regional 
emphysema severity dependent on genotype and were not identified based on differences 
in Lm measurements between lungs, I again standardized the Lm measurements within 
(A) (B) 
Figure 5. Gene expression profiles changing with emphysema severity dependent on SERPINA1 status. (A) 
Supervised heat map of 616 genes (uncorrected p < 0.01; 197 expected by chance) associated with the interaction 
between the natural log of Lm and emphysema subtype. Samples (columns) are supervised first by group and 
then within each group from mild to severe emphysema (left to right). Rows represent genes, are z-score 
normalized and hierarchically clustered, resulting in three columns (1 - pink, 2 - green, and 3 - orange). (B) The 
z-scored mean of each of these three clusters is plotted against the natural log of Lm, colored by group, and a 
best fit line is added. 
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each lung and reran the statistical analysis. This analysis revealed 231 genes (uncorrected 
p < 0.01) associated with standardized emphysema severity and dependent on genotype, 
124 of which were included in the original 616 genes (p < 0.0001 by Fisher’s exact test). 
 
 
Relationship to expression profiles induced by activation of the UPR 
To further test the relationship between the 222 genes from cluster 3 (orange cluster, 
Figure 5) and the unfolded protein response, which is known to be disrupted in the liver 
in AATD, I used GSEA to test whether the genes induced by activation of the UPR are 
enriched with genes from cluster 3. There are three arms of the UPR, each regulated by a 
different transcription factor, namely ATF4, ATF6, and XBP1. Cluster 3 genes were 
enriched amongst the genes most induced by overexpression of ATF4 compared to empty 
vector control in BEAS2B cells (p < 0.001) [21]. This cluster was similarly enriched 
amongst genes induced by orthogonal, small-molecule-mediated activation of ATF6 
(trimethoprim treatment) or XBP1 (dox treatment) in HEK293 cells (p < 0.001) [61]. 
Tunicamycin is a classic inducer of the UPR that leads to the accumulation of proteins in 
the ER, similar to what occurs in the liver of AATD patients. Cluster 3 genes were 
enriched amongst the genes most induced by tunicamycin treatment of immortalized B 
cells compared to DMSO treatment (p < 0.001) (Figure 6) [62].  
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Table 3. Enrichment results for genes from cluster 3, which have no relation to Lm 
in MM lungs yet increase with Lm in ZZ lungs (q < 0.05). 
Category FDR q value 
Unfolded protein response (Homo sapiens) 0.003 
N-glycan trimming and elongation in the cis-
Golgi (Homo sapiens) 0.004 
Nucleolus 0.008 
Protein export (Homo sapiens) 0.017 
Protein processing endoplasmic reticulum 
(Homo sapiens) 0.039 
Spliceosome (Homo sapiens) 0.039 
Extracellular vesicular exosome 0.044 	
Tunicamycin XBP1 Activation ATF6 Activation ATF4 Overexpression 
Figure 6. Genes increasing with emphysema severity in AATD are induced with activation of the unfolded 
protein response. Cluster 3, with genes increasing specifically in AATD emphysema, is enriched amongst genes 
most induced by ATF4 over-expression in BEAS2B cells, ATF6 or XBP1 activation in HEK293 cells, or 
treatment with tunicamycin in immortalized B cells (GSEA p < 0.001). In each of the figures, the red to blue 
color bar represents the set of all measured genes, with red representing genes induced by UPR activation, and 
blue representing genes reduced by UPR activation.  
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Discussion 
The goals of this study were to identify the gene expression changes associated with 
emphysema severity among lungs with and without alpha1-antitrypsin deficiency, and to 
identify any effects associated with one subtype or the other. By analyzing the 
transcriptome throughout ten explanted emphysematous lungs, I have identified gene 
expression changes common to both forms of emphysema and changes unique among the 
AATD lungs related to the UPR. 
 
Campbell and colleagues previously identified a 127-gene signature of emphysema 
severity that was enriched with genes involved in tissue remodeling and wound repair. 
Specifically, they found that genes modulated as part of the TGFb signaling pathway 
were down regulated with emphysema severity, and were regulating collagen contraction. 
Their reversal by treatment with TGFb1 rescued a collagen contraction deficit in 
fibroblasts taken from GOLD stage IV COPD patients with severe emphysema [28]. In 
the present study, this gene expression signature was enriched with genes that changed 
with emphysema severity among MM and ZZ lungs in the parenchymal tissue. This 
finding suggests that there are mechanisms of disease pathogenesis and progression that 
are shared between MM and ZZ emphysematous lungs, even though the emphysematous 
destruction and clinical picture manifest differently in each group. One previous study 
has examined transcriptomic differences between “usual” and AATD-associated 
emphysema [25] and the authors reported that these two emphysema subtypes shared 
many transcriptomic changes. The concordant enrichment of the 127-gene signature in 
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both subtypes provides further evidence for this observation. Furthermore, I was unable 
to identify any genes significantly differentially expressed between the two subtypes. In 
the rest of this study, I set out to further characterize the similarities across the subtypes 
and to identify any existing transcriptomic differences associated with worsening 
emphysema that do depend on the ZZ mutation. 
 
The 127-gene signature was reversed not only by treatment with TGFb1, but also by an 
endogenous, copper binding tripeptide, GHK [28]. As this transcriptionally identified 
compound and others similarly identified make their way into routine clinical care, 
characterization of the transcriptomic similarities and differences between emphysema 
and AATD-emphysema – the primary inherited form of the disease – will become 
increasingly important in order to predict the patients for whom these compounds will be 
effective. Identification of shared pathways may not only provide insight into 
pathogenesis, but may highlight potential additional therapeutic avenues going forward. 
Here, I identified 571 genes related to epithelial repair that decreased with emphysema 
severity, regardless of genotype. 
 
Axonal guidance cues are molecules that are known to guide axonal growth, but more 
recently have been shown to play a critical role in lung growth, angiogenesis, and repair. 
Vadivel and colleagues [63] demonstrated that airspace enlargement in newborn rats was 
associated with decreased lung EphrinB2 (EFNB2), an axonal guidance cue that was 
among the genes that decreased with emphysema severity. More broadly, we know that 
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whatever the cause, epithelial repair in the lung is deficient in emphysema. In the normal 
lung, epithelial restitution involves epithelial cell spreading and migration to cover the 
denuded area. These cellular dynamics require actin regulation for the establishment of 
cellular polarity and the extension of lamellipodia in the direction of migration. During 
migration, the actin cytoskeleton interacts with focal adhesions, and integrins associate 
with components of the extracellular matrix for traction [64]. Among the genes that 
decreased with emphysema severity were genes associated with focal adhesions, ECM 
and lamellipodium organization, migration of epithelial cells, and regulation of the actin 
cytoskeleton, all processes critical to lung re-epithelialization and repair [64]. 
 
There are many clinical challenges encountered in the treatment of emphysema. Among 
them are a lack of understanding of pathogenesis, a lack of treatments, and a lack of 
available biomarkers. Most of the gene expression profiles that changed with Lm 
decreased with increasing severity. However, among the 126 genes that increased with 
severity was SFTPD, the gene coding for surfactant protein D, a marker of lung damage 
[42] and potential biomarker of COPD and emphysema severity [40, 41, 43, 65, 66]. 
Surfactant protein D is a protein involved in marking apoptotic cells for immune-cell 
mediated clearance [44] and its increasing with damage in emphysema supports evidence 
pointing towards increased apoptosis as one of the pathogenic mechanisms in this disease 
(REF). Others have observed a relationship between serum levels of SFTPD and 
emphysema before [41] but none have measured it repeatedly within a single lung nor 
measured it at the level of gene expression. That the expression of SFTPD increased with 
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emphysema severity within a single lung, regardless of the SERPINA1 genotype, 
suggests it may be a dynamic biomarker of disease severity that could be used to track 
disease progression and not only facilitate diagnosis.  
 
Alpha1-antitrypsin deficiency associated emphysema may not represent the same public 
health burden as “usual” emphysema, but it leads to more severe and earlier onset disease 
that places a larger disease burden on those diagnosed. Accumulation of the ZAAT 
protein in the liver leads to cirrhosis and hepatocellular carcinoma and decreases the 
amount of functional AAT in circulation. The loss of AAT allows unchecked destruction 
of the lung tissue by neutrophil elastase, at least partly explaining the emphysema 
associated with AATD. Recently, the ZZ protein has been shown to accumulate not only 
in hepatocytes, but also in bronchial epithelial cells [51], suggesting that the lung may 
play a role in its own destruction. One study showed that accumulation of the ZZ protein 
hypersensitized hepatocytes to ER stress, which, upon secondary ER insult, more readily 
lead to induction of the unfolded protein response (UPR) and apoptosis [54]. The UPR 
primarily supports cell survival and its activation has many downstream effects, mediated 
through three arms. One arm, regulated by PERK and ATF4, transiently decreases the 
translation rate to decrease a cell’s protein folding burden [67-69]. A second arm, 
regulated by ATF6, increases the amount of protein folding chaperones [70, 71]. The last 
arm, regulated by IRE1a and XBP1, increases ER associated degradation [72, 73], and 
activates autophagy for better energy homeostasis [74, 75]. In the face of chronic, 
unresolvable ER stress, however, the UPR can instead lead to cell death [76]. Among the 
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AATD dependent genes, cluster 3 was enriched with genes involved in the UPR (Table 
3), including genes involved in protein processing, protein export, and ER associated 
degradation (e.g. SERP1, DNAJB9, DNAJC1, DNAJC21, SEC62, SEC63, and 
HSP90B1). I further demonstrated that cluster 3 genes were enriched with genes induced 
by each of the three arms of the UPR or by treatment with tunicamycin (Figure 6). This is 
all to suggest that genes involved in the UPR are increasingly activated with worsening 
emphysema severity uniquely among AATD lungs. Given the role that accumulation of 
the ZZ protein plays in the manifestation of liver disease in the setting of AATD, 
increasing UPR activity associated with worsening emphysema severity in the lungs of 
AATD patients should not be surprising, but it may have important implications for 
AATD emphysema pathogenesis. Specifically, if the ZAAT protein is accumulating in 
the cells of the lung like it accumulates in the liver and sensitizing pulmonary cells to 
secondary sources of ER stress (e.g. tobacco smoke), then providing AAT replacement 
therapy will be necessary but insufficient to treat this particular form of emphysema. The 
findings presented in this study suggest the lack of functional AAT is not the only 
problem in disease, but rather that the ZAAT protein has gained a toxic function that 
affects the pathogenesis of both liver and lung disease in AATD. 
 
Conclusions 
In the current study, I have uncovered genomic changes associated with emphysema 
progression in the lungs of patients with “usual” or AATD-associated emphysema. There 
are many shared changes between these two emphysema subtypes. Genes involved in 
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various aspects of wound repair decrease in expression with increasing emphysema 
severity, while SFTPD increases with disease severity, suggesting it could act as a 
biomarker of disease progression. Importantly, I was able to provide evidence that the 
unfolded protein response is increasingly activated with emphysematous destruction 
specifically in AATD. Not only do the lungs of these AATD patients have a decrease in 
genes involved in re-epithelialization, and a decrease in the amount of circulating, 
functional AAT, but the increasing activity of the UPR in these lungs may further 
exacerbate emphysema by favoring cell death in the face of chronic, unresolvable ER 
stress. 	  
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Chapter Four: Gene expression profiles associated with healthy alveolar spacing 
and emphysematous destruction  
Introduction 
 
Emphysema, or destruction of the functional alveolar tissue compartments of the lung, 
represents one pathologic aspect of chronic obstructive pulmonary disease (COPD), 
which is predicted to be the third leading cause of death worldwide by 2020 [77]. 
Tobacco smoke is the leading cause of emphysema and COPD, but not nearly all smokers 
develop pulmonary disease; approximately 25% of smokers develop COPD [14]. Though 
chronic cough, sputum production, and frequent infections are common symptoms of 
emphysema, dyspnea, or shortness of breath, is the most debilitating factor. 
Unfortunately, no emphysema modifying therapies exist and the disease inexorably 
progresses, even after smoking cessation. That the majority of long term, continuous 
smokers do not develop emphysema implicates genetic susceptibility as an important 
factor in disease pathogenesis, and also suggests the possibility that protective and repair 
mechanisms are sufficiently active in the majority of lungs. Cells of the normal, 
undamaged lung may turn over slowly, but rapid repair is possible. Epithelial cells 
migrate to cover denuded spaces, undifferentiated cells proliferate to replace the full 
epithelial layer, and tissue homeostasis can be restored as soon as 14 days post 
pulmonary injury [64, 78]. The exact mechanisms that regulate either emphysema 
pathogenesis or physiologically appropriate repair remain poorly characterized, but by 
improving our understanding of these processes we may learn to prevent emphysema 
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from occurring in the first place, or to augment the normal repair process in emphysema 
to reverse damage that accumulates over a lifetime of smoking.  
 
A process like emphysema is undoubtedly multi-faceted, but one widely accepted 
mechanism by which emphysema arises is an imbalance between the proteinases and 
anti-proteinases within the lung. Inhaled tobacco smoke recruits neutrophils [79], which 
are known to be increased in the lungs of patients with COPD, even after smoking 
cessation [80]. Neutrophils release a powerful elastase (i.e. neutrophil elastase, NE) 
capable of degrading the extracellular matrix and destroying the parenchymal tissue of 
the lung[81]. Patients with AATD, an inherited deficiency of the primary inhibitor of NE, 
have insufficient circulating alpha1-antitrypsin and so neutrophil elastase destroys the 
parenchyma, unchecked, leading to severe emphysematous destruction at an early age. 
Neutrophil recruitment to, and accumulation in the lung is not sufficient to cause 
emphysema, however, as acute inflammatory processes, like those seen in pneumonia, 
develop and resolve without permanent loss of functional tissue. Importantly, not all 
smokers develop appreciable disease, pointing towards the presence of additional 
mechanisms relevant for emphysema pathogenesis. 
 
Inflammation and proteolysis alone cannot explain emphysema and so other processes 
must be involved. Tobacco smoke not only recruits immune cells, but also causes damage 
through the production of reactive oxygen species (ROS) [82, 83]. The oxidative stress 
response and the unfolded protein response (UPR) normally help protect against ROS-
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induced damage. NFE2L2 (aka NRF2), the primary transcription factor that induces the 
expression of more than 100 anti-oxidant genes in response to ROS, has been shown to 
be disrupted in COPD [24, 84, 85]. Aspects of the UPR are also disrupted in disease [21, 
86, 87].  
 
Not only protective mechanisms, but also repair mechanisms are known to be disrupted 
in the lungs of patients with COPD and emphysema. Fibroblasts are normally responsible 
for deposition of extracellular matrix, a critical aspect of post-injury re-epithelialization, 
and have diminished repair capacity to produce ECM in COPD patients [88]. This 
deficiency may be regulated by the TGFβ signaling pathway [28], which is well known to 
be altered in COPD [25, 89-91]. Notch signaling is also important in alveolar 
morphogenesis and repair and is likewise disrupted in COPD [23, 26, 92-94]. Lastly, at 
least one study has demonstrated that epithelial cells in the lungs of patients from COPD 
have a diminished ability to migrate and cover a denuded space, thought to be the first 
step in repair of a damaged epithelium [64, 95]. Cell signaling, especially the Notch and 
TGFβ pathways, is disrupted in COPD and leads to observable phenotypic deficiencies in 
epithelial cell and fibroblast repair functions.  
 
Few studies have focused on profiling the gene expression programs active within a 
healthy lung. Cross-sectional transcriptomic studies include a non-diseased control group 
to be used as a baseline for comparison to a disease state, and any identified differentially 
expressed genes are interpreted in the context of the disease of interest. These kinds of 
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studies thus offer little insight into the activity of gene expression repair or protection 
programs in the normal lung and how they maintain homeostasis of the lung . One study 
to date has investigated in vivo the gene expression changes associated with normal repair 
[78]. These authors reported an increase in proliferating dedifferentiated cells and a 
tightly coordinated set of genes involved in cell cycle were present seven days post 
pulmonary injury, and that by 14 days post injury the airway epithelium appeared normal 
and gene expression alterations had reverted to baseline.  
 
The cells of the lung have been observed to be capable of proliferation, migration, and 
repair [63, 64, 78, 92, 94, 96, 97].  However, the mechanisms underlying these processes 
remain poorly characterized, and only in rare instances are otherwise healthy lungs 
collected for research, which is necessary for the elucidation of the normal processes 
occurring in the lung. In this study, I have leveraged data from five lungs from donors for 
whom no match could be found. These lungs were released for research and our 
collaborators at UBC subjected eight sections from each of these lungs to laser capture 
microdissection, separating airway and parenchymal tissue, and microCT to measure Lm. 
Members of our lab completed gene expression profiling on these sections. I have used 
these data to identify the genes and pathways that change with increasing alveolar 
spacing and to determine their relation to similar changes associated with emphysema. 
Campbell et al. previously completed a similar study including lungs mostly from 
patients with emphysema and identified TGFβ signaling as a pathway with genes 
decreasing with emphysema progression [28]. The goal of the present study is to identify 
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genes changing similarly and differently with alveolar spacing in healthy lungs and 
emphysema severity in diseased lungs. I report for the first time that there are genes 
associated with normal increases in alveolar spacing within healthy lungs, as measured 
by the mean linear intercept (Lm). Surprisingly, the majority of expression profiles 
positively associated with Lm in controls were negatively associated with Lm in diseased 
lungs, suggesting similar processes may be active in both groups but behaving 
differently. Macrophage M2 marker genes (e.g. MSR1, MARCO) were among the few 
genes that increased with Lm in both control and emphysematous lungs, while genes 
involved in TGFb signaling and its regulation (e.g. NEDD4, TGFbR1) increased in 
control and decreased with Lm in diseased lungs. 
 
Materials and Methods 
Microarray gene expression data analysis strategy 
I completed the following statistical analyses in a manner similar to a previous 
publication from our lab group [28]. In the expression data from the parenchymal tissue I 
utilized linear mixed effects modeling in conjunction with the likelihood ratio test (LRT) 
to identify differentially expressed genes associated with disease status (i.e. 
emphysematous tissue v control tissue) or emphysema severity and alveolar spacing (i.e. 
the natural log of Lm. Throughout the rest of this chapter I will simply refer to Lm, for 
easier reading). I undertook three separate analyses to identify (1) genes associated with 
group status, (2) genes changing with increasing alveolar spacing and emphysema 
severity across control and emphysematous lungs, and (3) genes changing with increasing 
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alveolar spacing differently than they change with emphysema severity. In each analysis, 
I identified a signature, compared the signature to a published data set or gene expression 
signature, and performed biological enrichment analysis. In the analyses examining gene 
expression effects associated with Lm, I also tested whether the signatures changed 
concordantly with Lm after standardizing Lm within each patient lung to a mean of zero 
and standard deviation of one (Z-Score). This helps to guard against patient outliers from 
disproportionately driving the makeup of the signature. For analysis 2, I further tested the 
consistency of the signature by similarly standardizing Lm within each group. This can 
help guard against a difference in the mean Lm between groups from affecting the Lm 
signature. 
 
I completed all statistical analysis in R v3.1.1. I used the R package nlme v3.1-128 for all 
LME modeling and I compared nested LME models by analysis of variance (ANOVA) 
using LRT. In some cases I used gene set enrichment analysis, GSEA v2.2.3 [59] to 
perform comparative genomic analysis. Any signatures I identified I also hierarchically 
clustered prior to biological enrichment analysis, which I completed with Enrichr [60], 
with the search space limited to KEGG, Biocarta, Reactome, and gene ontology (GO) 
databases. 
 
Analysis 1. Gene expression differences between emphysema and control lungs 
To identify genes associated with disease status I generated two models and compared 
them by the LRT: 
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(1) Gene ~ slice + ln(Lm) + random(patient) + error 
(2) Gene ~ slice + ln(Lm) + disease + random(patient) + error 
Here, slice represents the height from which a sample was taken from within a lung, 
ln(Lm) represents alveolar spacing or emphysema severity, and disease represents a 
binary variable denoting whether the tissue is from an emphysematous or from a non- 
emphysematous lung.  
 
Analysis 2. Gene expression changes associated with alveolar spacing and emphysema 
severity 
I next wanted to identify genes changing with increasing alveolar spacing and 
emphysema severity – i.e. Lm – consistently across control and emphysematous lungs 
and utilized the following modeling schema, again comparing models with the LRT: 
(3) Gene ~ slice + disease + random(patient) + error 
(4) Gene ~ slice + disease + ln(Lm) + random(patient) + error 
 
Analysis 3.  Gene expression changes associated with alveolar spacing or emphysema 
severity 
Finally, I wanted to identify any gene expression profiles associated with alveolar 
spacing differently than they are associated with emphysema severity. I did so by 
identifying gene expression profiles better fit to a model that includes the interaction 
between Lm and group than to a model that does not include the interaction: 
(5) Gene ~ slice + disease + ln(Lm) + random(patient) + error 
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(6) Gene ~ slice + disease + ln(Lm) + disease:ln(Lm) + random(patient) + error 
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Results 
Study Population 
Our collaborators at the University of British Columbia (UBC) measured Lm using 
micro-CT scans taken from regularly spaced regions from within the lungs of five 
patients with emphysema and five organ donors with intact lungs released for research. 
As expected, the lungs from patients with emphysema had a higher mean Lm than the 
lungs from the organ donors with no appreciable emphysema (p < 0.0001) (Figure 7). 
Table 4 shows demographic, clinical, and imaging information for the 10 lungs. The five 
diseased lungs were characterized by centrilobular emphysema (CLE).  
 
Table 4. Demographic information for the 10 lungs, five from emphysematous smokers, and five from 
donors for whom an appropriate match could not be found. 
Patient	 Group	 Sex	 Age	 PackYears	 Smoker	 LMSummary	 LMRange	
6996	 Emphysema	 F	 77	 45	 former	 512	(176)	 340-903	
7305	 Emphysema	 F	 58	 30	 former	 823	(99)	 715-967	
7307	 Emphysema	 M	 55	 80	 former	 959	(718)	 475-2635	
7336	 Emphysema	 F	 59	 40	 former	 572	(232)	 371-1102	
7337	 Emphysema	 F	 53	 24	 former	 1397	(536)	 839-2363	
6991	 Control	 F	 65	 unknown	 former	 400	(44)	 348-491	
6994	 Control	 M	 64	 15	 current	 389	(38)	 346-429	
7008	 Control	 M	 42	 15	 current	 353	(33)	 305-398	
7300	 Control	 M	 53	 0	 never	 381	(16)	 360-405	
7309	 Control	 M	 77	 0	 never	 339	(36)	 296-389		
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Genes differentially expressed between emphysematous and control lungs 
 Before investigating the gene expression effects of Lm in these 10 lungs, I wanted 
to identify any genes that differentiated the two groups, characterize the biology of these 
Figure 7. Distribution of natural log of Lm measurements by disease status. Each patient is 
represented by a different color and has up to eight samples. The samples from the 
emphysema patients have a significantly higher distribution than the controls (p < 0.0001). 
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changes, and compare these lungs to similar, previously published samples.  With linear 
mixed effects models controlling for height within the lung (i.e. slice), alveolar spacing 
(i.e. Lm), and a random patient effect, I identified 112 genes that were differentially 
expressed between emphysematous and control lungs (q < 0.01) (Figure 8A). 
Hierarchical clustering generated two clusters of genes, one with 60 genes increased in 
emphysema, and one with 52 genes decreased in emphysema. With a list of genes ranked 
by their association with group (i.e. the t-statistic for the coefficient of group from the 
model), I performed an enrichment analysis with GSEA [59] to identify pathways 
changing with disease status. Pathways involved in artery development were enriched 
with genes increased in emphysematous tissue, while pathways involved in ribosome 
biogenesis, mitochondrion, and energy metabolism, were all enriched with genes that 
		 47 
decreased (q < 0.001). 
 
Connection to independent emphysema dataset 
To test whether the gene expression differences observed here were conserved in other 
emphysematous tissue, I ranked genes by their association (i.e. t-statistic) with 
emphysema in Campbell et al.’s [28] cohort of emphysematous (n=5) and control lungs 
(n=2). The two clusters of 60 up and 52 down genes were concordantly enriched in this 
independent dataset (q < 0.001) (Figure 8B).  
 
Control 
Emphysema 
Disease 
Up in 
Emphysema 
Down in 
Emphysema 
Figure 8. (A) 112 genes are differentially expressed between emphysematous and healthy, donor lungs. 
These genes are broken into two clusters by hierarchical clustering, one set of genes repressed (top cluster) 
and one induced in emphysema (bottom cluster). In the heat map, each column represents a sample and 
each row a gene. (B) Each of these two clusters is significantly and concordantly enriched with genes that 
change between emphysematous (n=5) and control lungs (n=2) from Campbell et al.’s cohort (p < 0.001). 
(A) 
(B) 
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Genes associated with alveolar spacing and emphysema severity 
The true novelty of this project is not in characterizing gene expression profiles 
differentially expressed cross-sectionally across groups, but in its potential to identify 
gene expression profiles associated with increasing alveolar spacing in non-diseased, 
control lungs and emphysema severity in diseased lungs. Using linear mixed effects 
models, I identified 131 genes significantly associated with Lm across these 10 lungs (q < 
0.05) (Figure 9). Hierarchical clustering generated five clusters within these 131 genes. 
Due to the strong differences between the groups of lungs, coupled with the uncertain 
nature of Lm within non-emphysematous lungs, I wanted to confirm that these Lm-
associated genes were not being driven by any particular patient or by either group. To 
test whether any outlier patients were driving the results, I standardized the Lm 
measurements within each patient to a mean of zero and standard deviation of one (z-
score). I reran the analysis and tested with GSEA whether the 131 genes were enriched 
with genes that also changed with this standardized Lm measurement. To test whether the 
strong group difference in Lm (Figure 8) was driving the results, I next repeated this 
analysis after standardizing the Lm measurements within each group. In both patient and 
group-standardized Lm analyses, the five original clusters were concordantly enriched (q 
< 0.001) (Figure 9B, second column shows patient-standardized results; group-
standardized not shown). Clusters one and five increased with Lm, while clusters two, 
three, and four all decreased with Lm. Lastly, I wanted to test whether this Lm signal was 
detectable in each group separately or if it was being driven by one group in particular. I 
ranked genes by their association with Lm in each group and tested whether the five 
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clusters were enriched in the control lungs or in the emphysematous lungs. Cluster one is 
the only cluster enriched with genes that changed with Lm in controls (q < 0.001), while 
all five clusters were strongly enriched in emphysematous lungs (q < 0.001). Cluster one 
contained 42 genes, 26 of which were part of the core enrichment in both emphysematous 
and control lungs. Enrichr [60] revealed that these 26 genes were associated with the 
phagosome (q < 0.005 – MARCO, MSR1, NCF2, HLA-DRB1), monocyte differentiation 
(q < 0.05 – PDE1B, PPARG), activation of the immune response (q < 0.05 – MARCO, 
C1QA, SYK, MNDA, HLA-DRB1), and CD14+ Monocytes (q < 0.001 – DOK2, NCF2, 
SLC11A1, ALOX5, EMR1, C1ORF162, HK2). 
		 50 
 
Pathways and signatures changing with Lm  
The 131 genes were identified as genes associated with Lm across all 10 lungs. However, 
further interrogation of the five clusters they formed demonstrated that the majority of 
these genes (clusters two through four) were associated with Lm in emphysematous lungs 
only, and not in control lungs. To determine whether this lack of enrichment was due to a 
Figure 9. 131 genes are significantly associated with Lm across emphysematous (CLE) and healthy, 
donor lungs (q < 0.05). (A) These 131 genes are presented in a heat map, supervised by Lm from no 
emphysema to most severely emphysematous sample (left to right). Each column represents a sample 
and each row a gene expression profile. Hierarchical clustering identifies five clusters among these 
genes. (B) The z-scored mean of each gene cluster is plotted against the log of Lm and colored by group 
in the leftmost column and a best fit line is added. The second column shows that these clusters are 
enriched with genes that change even after standardizing Lm measurements within each lung to a mean 
of zero and standard deviation of one (GSEA q < 0.001). In the third and fourth columns, the five 
clusters are tested for enrichment with genes changing with Lm within either control or 
emphysematous lungs alone. Cluster one is significantly enriched in the same direction in both groups 
(p < 0.001). Clusters two through five are not significantly enriched in control lungs (p > 0.05). These 
clusters are strongly significantly enriched in emphysematous lungs (p < 0.001).  
Contro
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lack of appreciable Lm signal within the control lungs, or rather, due to Lm associated 
changes that could not be identified in a model including only a main effect of Lm, I 
tested whether other signatures associated with Lm were enriched in the controls and the 
emphysematous lungs separately. Campbell and colleagues [28] published a 127-gene 
signature of emphysema severity, and in the prior chapter I discovered a 571-gene 
signature of emphysema severity. I tested with GSEA the association of both of these 
signatures with Lm in controls and used the five emphysematous lungs as a positive 
control for comparison. Both gene signatures were concordantly enriched in the 
emphysematous lungs (p < 0.001). Campbell’s signature was significantly enriched in the 
opposite direction in controls (q < 0.001). Similarly, the genes decreasing with 
emphysema severity (chapter three signature) were enriched with genes that increased 
with Lm in controls (q < 0.001) (Figure 10C), changing in the opposite direction of that 
expected. 
 
The observation that two previously identified gene expression signatures of emphysema 
severity were enriched in control lungs in the direction opposite of that expected begs the 
question, what other genes or pathways change with Lm in controls and how do these 
changes compare to those occurring in emphysema? In each group of lungs, I ranked 
genes according to the t-statistic of the coefficient for Lm and tested with GSEA whether 
gene sets from KEGG, Reactome, Biocarta, and Gene Ontology were enriched with Lm-
associated genes. 1464 and 402 gene sets were significantly enriched with genes 
associated with Lm in control and emphysematous lungs, respectively (q < 0.05). 195 of 
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these gene sets were enriched with genes that increased with Lm in controls and that 
decreased with Lm in disease. Many of these 195 gene sets overlap, so I collapsed them 
into 12 gene sets involved in various processes including endothelial cell development, 
response to nutrient levels, proteasome mediated degradation, epithelial cell migration, 
and TGFβ signaling. Five of the gene sets were enriched with genes that increased in both 
control and diseased lungs, and I collapsed these into one gene set associated with 
peptide chain elongation (Figure 10A, 4B).  
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Figure 10. Gene sets from Biocarta, KEGG, Reactome, and 
Gene Ontological categories are enriched with genes that 
change with Lm in control and emphysematous lungs. (A) 
1496 and 402 gene sets are associated with Lm in control 
and emphysematous lungs, respectively (q < 0.05). 195 of 
these gene sets are enriched with genes that increase with 
Lm in control lungs and decrease with Lm in 
emphysematous lungs. (B) The 195 gene sets are overlapping 
and collapse into 12 sets of genes, which are involved in 
various processes including endothelial cell development, 
response to nutrient levels, proteasome mediated 
degradation, epithelial cell migration, and TGFβ - signaling. 
Five of the gene sets are enriched with genes that increase in 
both control and emphysematous lungs. Again, these 
collapsed into one gene set, which is associated with peptide 
chain elongation. The normalized enrichment scores for the 
13 collapsed gene sets, representing the strength of the Lm 
association, are plotted by group. (C) Campbell et al.’s 
signature and the emphysema severity signature derived in 
the previous chapter are concordantly enriched in 
emphysematous lungs, while they are partially enriched in 
the opposite direction in the control lungs.  
(A) 
Control 
Emphysema 
(B) (C) 
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Genes and pathways changing with alveolar spacing differently than they change with 
emphysema severity 
That 195 gene sets were enriched with genes that increased with Lm in controls and 
decreased with Lm in emphysematous lungs, raises the possibility that there are gene 
expression profiles that significantly that change with Lm in a group dependent manner 
(i.e. they associated with the interaction between Lm and group). I identified 883 gene 
expression profiles significantly associated with the interaction between Lm and disease 
(q < 0.1). These genes changed with alveolar spacing in control lungs differently than 
they changed with emphysema severity in diseased lungs, both as measured by Lm. 
Hierarchical clustering of these genes broke them into two clusters of 431 and 452 genes 
(Figure 11A). Cluster 1 (purple) decreased with Lm in controls and increased with Lm in 
emphysema, while cluster 2 (green) increased with Lm in controls and decreased with 
Lm in emphysema (Figure 11B). Cluster 2 was enriched with genes involved in TGFβ 
signaling, genes regulated by the vitamin D receptor, immune system genes, and genes 
involved in the DNA damage response (q < 0.005).  
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Figure 11. 883 genes are significantly associated with the interaction between Lm and disease status (q < 0.1). 
(A) These genes are presented in a heat map, which is supervised first by group, and then by increasing Lm 
from left to right. Each column represents a sample and each row a gene expression profile. Red represents 
relatively high expression and blue relatively low expression. Hierarchical clustering separates these into two 
sets of genes: cluster 1 (purple) with 431 genes and cluster 2 (green) with 452 genes. (B) The z-scored mean of 
these clusters is presented and a best fit line is added.  
Healthy 
Emphysema 
Disease 
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Discussion 
The goal of this study was to compare and contrast gene expression changes associated 
with normal alveolar spacing to gene expression changes associated with emphysema 
severity in order to identify aspects of the lung homeostasis and repair program and 
determine its connection to emphysema. In the long term, the identification of any 
connection between the homeostasis repair program and emphysema can improve our 
understanding of the deficiencies of repair present emphysema and guide us towards safer 
strategies for developing disease modifying therapies that are similar to the naturally 
occurring repair system. By collecting both control and emphysematous lungs, measuring 
gene expression at various points throughout each lung, and quantifying alveolar spacing 
at these points, our collaborative effort has identified stark differences in gene expression 
patterns occurring in control compared to emphysematous lungs.  
 
I compared group differences discovered here to previously profiled lungs and compared 
biological pathways enriched here to those previously reported. The genes decreased in 
emphysematous lungs are involved in energy maintenance and metabolism, consistent 
with what was previously observed when comparing emphysematous and control lungs 
[25]. Furthermore, there is a strong and clear connection to a previous gene expression 
dataset of emphysematous and control tissue [28] (Figure 8B). These two observations 
suggest that the lungs included in this study are similar to those previously profiled.  
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Across all 10 lungs, I identified 131 genes associated with Lm (Figure 9A). After 
thorough follow up, however, I discovered that these genes’ relationship with Lm was 
driven mostly by changes in gene expression with emphysema severity, and they bore 
little relationship to alveolar spacing in control lungs (Figure 9B). Yet, cluster one was 
associated with Lm in both emphysematous and control lungs, showing that some genes 
change with Lm regardless of disease. Cluster one included phagosome genes, monocyte 
markers, and genes involved in monocyte differentiation. MSR1 (a.k.a. CD204) is 
expressed by anti-inflammatory, alternatively activated (M2), alveolar macrophages, and 
these CD204+ macrophages have been shown to be increased in the lungs of patients 
with COPD at GOLD stages III and IV compared to stages I and II, and to non-smokers. 
The number of CD204+ macrophages was also shown to be negatively correlated with 
the percent predicted forced expiratory volume [98]. A coding single nucleotide 
polymorphism (SNP) in MSR1, SNP P275A, is also associated with susceptibility to 
COPD and a lower forced expiratory volume to forced vital capacity ratio (FEV1/FVC) 
[99]. M2 macrophages serve many purposes. Using phagocytosis, they clear bacteria and 
cellular debris from damaged tissue; they also secrete TGFβ, promote angiogenesis, and 
support wound healing [100-102]. In this study, I have shown that macrophage associated 
genes increased with Lm in both control and emphysematous lungs. This suggests there 
are more M2 macrophages present in pulmonary sections with higher Lm values, 
regardless of disease status. In emphysematous lungs, the Lm measurement clearly 
indicates degree of damage, yet the biological interpretation of Lm in controls is not so 
readily apparent. The suggested increase in macrophages with Lm in controls can be 
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further extrapolated to suggest that increasing Lm in control lungs – while it does not 
represent damage to the degree seen in emphysema – may indicate minor amounts of 
damage undergoing inflammation and repair.  
 
Though I was able to identify one cluster of macrophage associated genes increasing with 
Lm in both control and emphysematous lungs, the remaining four clusters were not 
enriched with Lm-associated genes in controls. This observation led me to question the 
nature of the Lm-associated gene expression changes in control compared to 
emphysematous lungs. Campbell et al.’s [28] 127-gene signature of emphysema severity 
(i.e. Lm) and my 571-gene set associated with emphysema severity were both 
concordantly enriched in the emphysematous lungs, but were reversed in the control 
lungs. Campbell’s signature is associated with TGFβ signaling, inflammation, and tissue 
repair. The emphysema severity signature (chapter 3) is enriched with genes involved in 
angiogenesis and the regulation of epithelial cell migration. Broadly, these are all part of 
the epithelial repair system, and their reversal in controls suggests that similar genomic 
epithelial repair programs are active in both groups but that they act differently between 
diseased and non-diseased lungs. I expanded this exploration to include pathway based 
gene sets from KEGG, Reactome, Biocarta, and the gene ontology categories, and 
discovered that 195 gene sets were enriched with genes that increased and decreased with 
Lm in control and emphysematous lungs, respectively (Figure 10A). These gene sets are 
involved in TGFβ signaling, among other things. TGFβ signaling plays an important role 
in branching morphogenesis and epithelial differentiation in the developing lung [103], 
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and so this finding may represent one aspect of the developmentally conserved pathway 
active in lung maintenance and repair. This pathway has repeatedly been shown to be 
dysregulated in emphysema at both the gene expression and SNP level [28, 89, 91, 104, 
105], further implicating the pathway and highlighting possible drivers of dysfunction.  
 
Looking beyond the pathway based analysis, I wanted to determine if any genes were 
significantly associated with the interaction between Lm and disease-state in these 10 
lungs. That is, do any gene expression profiles change with alveolar spacing in control 
lungs differently than they do with emphysema severity in diseased lungs. The 
differences between alveolar spacing and emphysema severity are emphasized by the 
discovery of 883 such genes (Figure 11A). Again, these genes, which are involved in 
TGFβ signaling (e.g. SMAD4, TGFΒR1), decreased with emphysema severity and 
increased with Lm in control lungs. SMADs, key regulators of TGFβ signaling, are 
themselves regulated by the ubiquitination-proteasome pathway, specifically genes like 
SMURF2 and NEDD4, which are included in these 883 genes (cluster 2) [106]. NEDD4 
has also previously been associated with emphysema severity [56].  
 
Conclusions 
In this study, I have identified gene expression profiles changing with alveolar spacing in 
control lungs and determined that these changes sit in stark contrast to those observed in 
emphysematous lungs. Though macrophage markers like MSR1 and MARCO increase 
with both healthy alveolar spacing and emphysema severity, the majority of gene 
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expression profiles associated with Lm are positively associated with Lm in controls and 
negatively associated with Lm in emphysematous lungs. In emphysematous lungs, Lm is 
a well-established marker of alveolar damage, but the interpretation of Lm in non-
diseased lungs is less clear. The increase with Lm of the expression of macrophage 
marker genes, as well as genes involved in TGFβ signaling and its regulation, suggest 
that Lm measures normal alveolar damage undergoing healthy inflammation, resolution, 
and repair. The reversal of the relationship between these changes and Lm in emphysema 
implicates a deficiency of these normal processes as an important mediator of disease 
progression. One of the longstanding hypotheses of emphysema pathogenesis is that an 
imbalance between proteinases and anti-proteinases – brought about by increased 
pulmonary inflammation – leads to unchecked destruction of the parenchymal tissue. The 
observations presented in this study can push the field towards closer consideration of the 
aspects of emphysema that occur post tissue damage, namely a lack of functional tissue 
repair. In fact, inflammation occurs frequently in the lung without leading to emphysema, 
as is the case in pneumonia, and occurs as part of normal wound repair [107-110]. 
Therefore, the inflammation so frequently cited as a critical driver of emphysema may be 
secondary to the lack of repair, which cyclically leads to inflammation, more irreparable 
damage, and eventually the inexorable progress of emphysematous destruction. 	  
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Chapter Five: Transcriptomic connection between COPD and lung cancer 
implicates role for H3K27Me3 in COPD-associated pulmonary carcinogenesis 
Background 	
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and 
mortality in the United States. It is burdensome both to patients and to the health care 
system, and while it was the fifth most common cause of death in 1980, the Centers for 
Disease Control reported that it was the third most common cause of death in the U.S in 
2014 [1]. Approximately 15 million people are diagnosed with COPD (6.4% of the U.S. 
population) and these individuals are more likely to be unable to work, to have an activity 
limitation, and to have difficulty walking or climbing stairs [3]. Patients with COPD are 
also more likely to develop lung cancer.  
 
Skillrud and colleagues [4] observed for the first time in 1986 that COPD patients 
compared to healthy smokers had an increased rate of lung cancer development. These 
researchers prospectively compared COPD cases to controls matched for age, sex, 
occupation, and smoking history, and found that lung cancer developed more frequently 
in the patients with COPD. Matching by smoking history was critically important for this 
study because both COPD and lung cancer are both known to be caused by tobacco 
smoke. Recently, several groups have repeatedly to rediscovered the association between 
COPD and lung cancer [6-8, 31]. One meta-analysis of 39 studies calculated that the 
combined relative risk of lung cancer in COPD was 1.83 and demonstrated that diagnoses 
of COPD, chronic bronchitis, and emphysema all carried increased lung cancer risk [32]. 
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One important addition to these observations came from a study in 2014 that showed that 
tumors in the lungs of patients with COPD were more likely to originate in regions of 
severe emphysematous destruction [33]. Furthermore, alpha1-antitrypsin deficiency, 
which is associated with the most severe form of emphysema, also carries an increased 
lung cancer risk [34-36].  Whether COPD is an independent risk factor for lung cancer is 
still debated, and as recently as 2013, Powell et al. [5] suggested that smoking habit and 
the timing of COPD diagnosis could account for the observed increased incidence of lung 
cancer among COPD patients. When correcting for smoking and including only patients 
with a 10 year or greater history of COPD, however, this study still found that the odds of 
lung cancer development was greater among the COPD population (odds ratio: 2.18). The 
general consensus is that COPD increases lung cancer risk. 
 
Proposed mechanistic links between COPD and carcinogenesis 
At this point, the mechanisms that prime the lungs of COPD patients for malignant 
growth remain unclear, but the pathogenic processes of each individual disease are at 
least partially understood. The hallmarks of cancer include evading apoptosis, tissue 
invasion, and sustained angiogenesis. Interestingly the primary processes of COPD 
appear unrelated to or directly at odds with those of cancer: increased apoptosis, limited 
angiogenesis, ineffective tissue repair, and an intense immune response [111]. Chronic 
inflammation has been linked to cancer in a number of organs: hepatitis B and C, H. 
pylori, and ulcerative colitis have been shown to lead to cancers of the liver, stomach, and 
colon, respectively [112]. The chronic inflammation of COPD could similarly be 
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increasing the risk of lung cancer in these patients [111, 113]. Separately, the airway 
obstruction defining COPD may force the retention of airborne carcinogens, increasing 
the likelihood of cancer development. The retention of carcinogens could lead to errors in 
DNA repair, activation of oncogenes, repression of tumor suppressors, or oncogenic 
epigenetic alterations [9]. Apoptosis plays a role in both diseases, and at first glance the 
evasion of apoptosis in cancer appears at odds with the increased apoptosis observed in 
COPD. On the other hand, increased apoptosis leading to emphysematous destruction 
could select for a mutation-derived apoptosis resistance, which could increase the 
population of cancer stem cells in damaged regions of the lung. This could also explain 
the increased odds of a lung cancer developing in a highly emphysematous region [33]. 
 
While several links have been suggested as the key drivers of COPD-associated 
carcinogenesis, no consensus has yet been reached. The role of proto-oncogene c-Src has 
been established in lung cancer, and it plays a role in COPD pathogenesis as well. 
Research showed that the inhibition of c-Src decreased the activation of matrix 
metalloproteinases-9 and -12 in alveolar macrophages, and also decreased the lung 
expression of some proteins known to play a role in COPD pathogenesis, namely, 
cathepsin K, IL-17, TNF-alpha, CCL2, and CXCL1 [114]. Further research has 
implicated the oxidative stress pathway, inflammation, the epithelial-to-mesenchymal 
transition (EMT), altered DNA repair, cellular proliferation and NF-kappaB [115]. 
Muscarinic receptor 3 (M3R) may be important in both non-small-cell lung cancer 
(NSCLC) and COPD, as one study showed that its expression was increased with tumor 
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grade and in COPD. Additionally, M3R expression was able to promote migration and 
invasion in NSCLC cell lines [116]. The miRNA let-7 may provide another molecular 
link between COPD and lung cancer; let-7 was reduced in the sputum of COPD patients, 
and was associated with an increase in the expression of soluble tumor necrosis factor 
receptor 2 (TNFR2), a let-7 target. Let-7 expression was correlated with FEV1 and is a 
known tumor suppressor in lung cancer [117]. A number of reviews and original articles 
investigating the potential molecular links between COPD and lung cancer have been 
published in recent years [113-115, 118-125]. The list of genes and pathways currently 
implicated in the pathogenic relationship between COPD and lung cancer is quite 
extensive. Due to the heterogenous nature of each of the two diseases, the relative 
importance of any single gene or pathway has been difficult to evaluate and so no 
consensus has emerged.  
 
The goal of the present study is to provide a look at the genome wide connections 
between COPD and lung cancer that help explain the increased lung cancer risk in 
COPD. Hereafter, I provide evidence that genes regulated by H3K27Me3 are repressed in 
both COPD and lung cancer, and that these changes can help explain the inter-disease 
connection. Several known pulmonary tumor suppressors – SLIT2, WIF1, HPGD, and 
RAMP2 – are repressed in COPD, with emphysema severity, and in non-small cell lung 
cancer tumor tissue. These genes are regulated by the epigenetic histone mark, 
H3K27Me3, which is induced by the methyltransferase EZH2, the protein coding gene of 
which is up-regulated in the COPD lung. Clinical trials of EZH2 inhibitors for various 
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cancers are currently underway, and if safe and successful, could prove a disease 
modifying therapy in COPD and one that could decrease lung cancer risk among this 
debilitated patient population. 
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Methods 
Microarray data acquisition and normalization 
Many groups have profiled the gene expression patterns of lung tumors and adjacent 
normal lung tissue in an effort to further our understanding of the molecular events 
driving lung carcinogenesis. I have leveraged the publicly available gene expression data 
from four such studies [126-129] to connect transcriptomic changes seen in COPD and 
emphysema to changes seen in lung tumors. Adam Gower, Ph.D. (Boston University), 
obtained CEL files from the GEO repository for GSE10072, GSE27262, GSE44077, and 
GSE7670. He used the Robust Multiarray Average (RMA) [38] algorithm with an Entrez 
gene-specific probeset mapping (17.0.0) from the Molecular and Behavioral 
Neuroscience Institute (Brainarray) at the University of Michigan to normalize CEL files 
and produce gene-level expression values. 
 
Several groups have also undertaken genome wide gene expression studies of never, 
former, and current smokers, with and without COPD, to help elucidate molecular 
alterations defining the COPD disease state. In this study, I have leveraged data from four 
of these studies as well [21, 22, 24, 130]. The CEL files for GSE30063, GSE37147, 
GSE56341, and GSE11784 were obtained and normalized by Adam Gower in the same 
manner as the four cancer datasets. I also leveraged all ten emphysematous lungs from 
Aim 1.  
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Testing COPD and emphysema gene expression signatures in lung tumors 
Members of our lab previously described a 98-gene expression signature of COPD in the 
airway [21] and a 127-gene signature of emphysema severity in lung tissue [28]. In aim 1 
of this thesis, I also discovered a 571-gene set associated with emphysema severity across 
both “usual” and alpha1-antitrypsin deficiency associated emphysema. I hypothesized 
that these disease-associated transcriptomic alterations would be altered in lung tumors as 
well as in COPD and emphysema, and that any overlapping changes between the two 
disease states could help explain the increased risk of lung cancer development observed 
in patients with COPD. I tested with gene set enrichment analysis (GSEA) [59] whether 
these three gene sets were enriched with genes that changed in tumors compared to 
adjacent normal tissue. To determine the relative strength of the enrichments I also tested 
whether gene sets from MSIGDB were enriched with genes changing between tumor and 
adjacent normal tissue. 
 
Differential expression analysis in tumors and adjacent normal tissue 
Tumor tissue is different from adjacent normal tissue both in terms of the patterns of 
observable gene expression and in the ratios of the extant cell populations. Therefore, any 
enrichment of COPD related gene sets observed between tumor and adjacent normal 
tissue may simply be due to the large scale transcriptomic differences observed between 
tumors and adjacent normal tissue. To guard against this possibility I derived four gene 
expression signatures, one for each of the four cancer datasets. I used the limma package 
[131] in R to identify genes differentially expressed between tumors and adjacent normal 
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tissue with an absolute log fold change greater than or equal to 1.5 and FDR less than 
0.01. I then tested with GSEA, whether these tumor-associated signatures were enriched 
with genes that changed with COPD or with emphysema severity. The enrichment of 
tumor signatures in COPD lungs would suggest that any enrichment of COPD signatures 
in tumor data was not a false positive driven by the large scale transcriptomic alterations 
present in tumors compared to adjacent normal tissue. 
 
Functional enrichment analysis 
I used Enrichr [60] to identify functionally enriched biological categories present in the 
COPD, emphysema, and lung tumor signatures. I limited the search to databases of genes 
associated with transcription factors, histone modifications, canonical pathways from 
KEGG, Reactome, Biocarta, and gene ontology categories. 
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Results 
GEO Microarray Datasets 
The four lung cancer studies were comprised of samples from 148 individual patients 
(Table 5). Most but not all patients had paired tumor and adjacent normal tissue available. 
All tumor data came from studies of non-small cell lung cancer (NSCLC), specifically 
adenocarcinomas. The tumors profiled were from stages IA to stage IV (Table 5).   
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Table 5. Demographics for four publicly available lung cancer data sets that include paired tumor and 
adjacent normal data from 148 patients. Not all studies had all demographics included, denoted as “-“.  
* NSCLC – not further specified 
	 Landi (2008) Wei (2012) Kadara (2014) Su (2007) 	 GSE10072 GSE27262 GSE44077 GSE7670 
Patients 74 25 23 26 
Gender 	 	 	 	
Female 27 - - 21 
Male 47 - - 5 
Age 66.43 (7.45) 58.12 (12.63) - - 
Smoking Status 	 	 	 	
Current 28 - - - 
Former 26 - - - 
Never 20 - - - 
Tumor type Adenocarcinoma Adenocarcinoma NSCLC* Adenocarcinoma 
Stage 	 	 	 	
IA 8 7 - - 
IB 22 18 - - 
IIA 4 0 - - 
IIB 22 0 - - 
IIIA 11 0 - - 
IIIB 4 0 - - 
IV 3 0 - - 	
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The four COPD studies are comprised of 523 never and ever smokers, 153 of whom had 
COPD (Table 6). One study included 60 never smokers [22] (Table 6). Demographics 
information for the 10 emphysematous lungs can be found in Aim 1.  
  
Enrichment of COPD and emphysema signatures in lung tumors 
I tested whether three signatures of COPD and emphysema [21, 28] (and Aim 1) were 
enriched with genes that changed between lung tumors and adjacent normal tissue. I 
similarly tested whether 1077 gene sets from MSIGDB (KEGG, Reactome, and Biocarta 
Table 6. Demographics for four publicly available COPD microarray data sets that 
include airway brushings from 523 never and ever smokers with or without 
COPD. Not all studies had all demographic information included, denoted as “-“.  
	 Tilley (2011) Steiling (2013) Vucic (2014) Wang (2012) 	 GSE11784 GSE37147 GSE56341 GSE30063 
Patients (n = 94) (n = 238) (n = 22) (n = 169) 
COPD 	 	 	 	
no 72 151 14 133 
yes 22 87 8 36 
Gender 	 	 	 	
Female 24 103 8 - 
Male 70 135 14 - 
Age 44.6 (8.7) 64.53 (5.88) 63.95 (4.56) - 
Smoking 	 	 	 	
Never 0 0 0 60 
Ever - - - 109 
Current 94 99 0 - 
Former 0 139 22 - 	
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canonical pathway gene sets) were enriched, to determine the relative strength of the 
enrichments of the COPD and emphysema signatures. For these enrichment analyses I 
broke the three gene sets into sets of genes up or down regulated with disease. I generated 
one ranked list of genes per cancer dataset and ordered the genes by the t-statistic of the 
coefficient for tissue (i.e. tumor v adjacent normal). The three sets of genes down 
regulated in COPD or with emphysema severity were strongly negatively enriched in all 
four tumor datasets (q < 0.05). These down-regulated gene sets were the most negatively 
enriched among all of the gene sets tested. The three sets of genes up regulated in COPD 
or with emphysema were positively enriched in two of the four tumor datasets (q < 0.05) 
but were not among the most positively enriched gene sets (Figure 12A). The decreased 
genes from the emphysema and COPD signatures were strongly negatively enriched and 
clearly decreased in tumor compared to adjacent normal tissue (Figure 12B: Aim 1 genes 
projected into tumor data as exemplar [129]).  
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Identification of differentially expressed genes in tumors compared to adjacent normal 
tissue 
Tumors and adjacent normal tissue are grossly different. In each of the four datasets I 
identified a set of genes with an absolute log fold change greater than or equal to 1.5 and 
Figure 12. Gene sets decreased with emphysema severity and in COPD are decreased in lung tumor tissue. 
Our lab has previously published a 127-gene signature of emphysema severity (Campbell et al.) and a 98-
gene signature of COPD (Steiling et al.). In Aim 1 of this document I also discovered a 571-gene set 
associated with emphysema severity across both “usual” and alpha1-antitrypsin deficiency associated 
emphysema. (A) From these three signatures, the genes that were decreased with emphysema severity or 
decreased in COPD lungs were consistently negatively enriched in tumors compared to adjacent normal 
tissue across four independent gene expression profiling experiments (Landi et al., Wei et al., Kadara et al., 
and Su et al.), by GSEA (q < 0.05). In this figure, each row represents a ranked list of genes from a 
microarray dataset of tumor and adjacent normal tissue. Genes were ranked according to the t-statistic of 
the coefficient for tissue (i.e. tumor v adjacent normal tissue). Each column represents the up or down 
regulated portion of each of the three signatures associated with COPD or emphysema. The blue-red color 
bar, as well as the size of the colored circle, represents the strength of the enrichment of the signature in 
tumor compared to adjacent normal tissue, i.e. the normalized enrichment score (NES) for each set of genes 
from GSEA. Blue indicates a negative enrichment score (genes decreased in tumors) and red a positive 
enrichment score (genes increased in tumors). An “X” denotes that the gene set was not significantly 
enriched (q > 0.05) I also tested whether 1077 gene sets from MSIGDB (KEGG, Reactome, and Biocarta) 
are enriched in the 4 cancer datasets. The numbers in each circle represent where in the list of negatively or 
positively enriched gene sets each of the COPD and emphysema signatures fall. E.g. Among gene sets down 
regulated in Landi’s 2008 study, the set of genes down-regulated from Aim 1 is the top-most down-
regulated gene set and Campbell’s set of down genes is second. (B) In Landi et al.’s tumor and adjacent 
normal tissue, the expression profiles of the genes decreasing with emphysema severity (Aim 1) are 
visualized; they display a clear down-regulation of genes decreased with emphysema severity in lung 
adenocarcinoma tissue compared to adjacent normal tissue. 
Adjacent Normal 
Tissue Adenocarcinoma 
Tissue 
(B) (A) 
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FDR < 0.01 (Table 7) and subsequently tested the enrichment of these gene sets in the 
four COPD studies. 
  
COPD and emphysematous lungs enriched with tumor associated gene expression 
changes 
I tested with GSEA the enrichment of the sets of genes differentially expressed between 
NSCLCs and adjacent normal tissue (Table 7) in COPD and emphysematous lungs. The 
sets of genes increased in tumors were consistently enriched with genes increased in the 
lungs of COPD patients or with genes increasing with emphysema severity (q < 0.05 in 
all five data sets). The sets of genes decreased in tumors were enriched with genes 
decreased in COPD or with emphysema severity (q < 0.05 in four of five data sets) 
(Figure 13).  
 
 
Table 7. Number of genes with an absolute 
fold change greater than or equal to 1.5 and 
FDR < 0.01 in each of the four tumor and 
adjacent normal studies.  
First Author GEO Access # Up Down 
Landi GSE10072 65 131 
Wei GSE27262 264 480 
Kadara GSE44077 143 273 
Su GSE7670 41 155 	
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COPD, emphysema, and lung cancer signatures associated with H3K27Me3 
Using Enrichr [60], I discovered that the gene sets decreased in COPD, with emphysema 
severity, or in lung tumors, were all enriched with genes associated with H3K27Me3 and 
SUZ12 (q < 0.05) (Figure 14A). SUZ12, EED, and EZH2 are the three genes that code 
for the subunits of the polycomb repressor complex 2 (PRC2), which is responsible for 
Figure 13. Genes with an absolute fold change greater than 1.5 (q < 0.01) in tumor compared to adjacent 
normal tissue are enriched in COPD and emphysema datasets. Columns 1-4 and columns 5-8 represent sets of 
genes increased and decreased in tumor compared to adjacent normal tissue, respectively, from GSE10072, 
GSE27262, GSE44077, and GSE7670. Each row represents a ranked list of genes from a microarray dataset 
of COPD or emphysema. In the COPD datasets, genes were ranked according to the t-statistic of the 
coefficient for disease (e.g. smoker with COPD v healthy smoker), and in the emphysema dataset (10 lungs 
from aim 1), genes were ranked according to the t-statistic of the coefficient for emphysema severity. The 
blue-red color bar, as well as the size of the colored circle, represents the strength of the enrichment of the sets 
of tumor-associated genes in the COPD and emphysema datasets, i.e. the normalized enrichment score (NES) 
for each set of genes from GSEA. Blue indicates a negative enrichment score (genes decreased in COPD or 
with emphysema) and red a positive enrichment score (genes increased in COPD or with emphysema). An 
“X” denotes that the gene set was not significantly enriched (q > 0.05). 
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trimethylating the 27th lysine of histone 3 (H3K27Me3), a histone modification 
responsible for repressing many genes involved in developmental pathways. EZH2 codes 
for the methyltransferase that actually generates H3K27Me3. Using Fisher’s method for 
combining independent tests baring on the same question, I tested whether each of these 
three genes were differentially expressed by COPD status within and across the four 
COPD data sets. EZH2 was significantly up-regulated in three of the four datasets (p < 
0.05) and was significantly up-regulated when combining all data sets (p < 0.0001). 
Neither SUZ12 nor EED were differentially expressed by COPD status. I similarly tested 
the three genes between tumors and adjacent normal tissue. Each of the genes was 
differentially up-regulated in tumors compared to adjacent normal tissue, both in and 
across the four tumor datasets (p < 0.001).  (Figure 14B).  
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Figure 14. Genes decreased in tumors, in COPD or with emphysema severity are associated with 
H3K27Me3 and angiogenesis. (A) Enrichment results from each set of genes down-regulated in tumors, in 
COPD, or with emphysema are overlapping. Here, each row represents one of the disease associated gene 
sets tested for enrichment in any biological categories (e.g. Aim 1 down genes). Each column represents an 
enrichment term significantly associated with at least six of the seven tested signatures. The green color 
and size of each square represents the -log(q) value for the enrichment and each green square represents a 
significant enrichment result (q < 0.05). Genes regulated by H3K27Me3 are enriched among all of the 
gene signatures. SUZ12 codes for a subunit of the polycomb repressive complex 2 (PRC2), which is 
responsible for the trimethylation mark H3K27Me3. (B) The three subunits of PRC2 are EED, SUZ12, 
and EZH2. Fisher’s combined probability test allows meta-analysis of disparate data sources by 
combining p-values for independent tests baring on the same hypothesis. Combining the results across the 
cancer datasets shows that each of these three subunits is over-expressed in tumors compared to adjacent 
normal tissue. EZH2 is also over-expressed in the lungs of COPD patients compared to healthy smokers 
(B: left most panel). EZH2 expression is increased in COPD lungs compared to healthy smoker lungs in 
GSE37147 (B: middle panel) and in tumors compared to adjacent normal tissue in GSE44077 (B: right 
most panel). 
(A) 
** p < 0.001 *** p < 0.0001 p > 0.05 p < 0.05 
(B) 
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The association of the COPD, emphysema, and tumor genes sets with H3K27Me3 was 
due to 75 genes from these gene sets. These genes were either decreased in tumors and in 
COPD (e.g. SLIT2, WIF1) or decreased in tumors and with emphysema severity (e.g. 
EPAS1). No genes were decreased in all gene sets (Figure 15).  
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Figure 15. The sets of genes decreased in tumors, COPD, and emphysema are enriched with genes involved 
in angiogenesis and regulated by H3K27Me3. These enrichments are associated with 75 genes that overlap 
across gene sets and enrichment terms. Each row represents either a disease gene set or enrichment term. 
Each column represents a single gene. A blue box means that the gene is a member of the gene set or 
enrichment term. Genes are sorted such that genes that are members of the most signatures and enrichment 
terms are to the left, and those that are members of the fewest signatures or enrichment terms are to the 
right.  
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Discussion 
Patients with chronic obstructive pulmonary disease are at increased risk of developing 
lung cancer. The goal of this study was to identify shared transcriptomic alterations in 
lung cancer and COPD that could drive carcinogenesis in COPD. I have identified 
H3K27Me3 (trimethylation of histone 3 on lysine 27) and EZH2 – the gene coding for 
the methyltransferase responsible for the histone modification – as a potential epigenetic 
regulator of COPD and lung cancer, and a shared regulatory event that could drive the 
increased lung cancer risk observed among COPD patients. I demonstrated that sets of 
genes decreased in COPD and with increasing emphysema severity were strongly 
enriched with genes decreased in tumors (Figure 12), even more so than gene sets 
associated with canonical pathways. Interestingly, the genes decreasing with emphysema 
severity are at their lowest expression levels in the most damaged regions of 
emphysematous lungs, and are also decreased in tumors. To an extent then, cells 
surviving in the damaged regions of the lung are transcriptomically similar to tumors, 
which is in line with the observation that tumors are more likely to arise in these damaged 
regions [33].  
 
H3K27Me3 and EZH2 
Gene expression signatures of COPD and emphysema were enriched in tumor tissue and 
gene sets differentially expressed between tumor and adjacent normal tissue were 
enriched in COPD and emphysematous lung (Figure 13). These observations suggest that 
these disease states are transcriptomically similar, if pathologically different. Moreover, 
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all of these interconnected gene sets were enriched with genes regulated by H3K27Me3 
and SUZ12 (Figure 14), which is part of the polycomb repressor complex 2 (PRC2) 
responsible for generating H3K27Me3 [132]. PRC2 is made up of SUZ12, EED, and 
EZH2, the enzymatic methyltransferase actually responsible for the action of PRC2, and 
EZH2 was significantly overexpressed in the lungs of COPD patients (Figure 14). EZH2 
overexpression has been observed in gastric, ovarian, breast, bladder, and lung cancers 
and is often associated with a worse prognosis [133-142]. Overexpression of this 
methyltransferase has been demonstrated to be oncogenic in mice but insufficient to drive 
carcinogenesis 100% of the time. Approximately 45% of mice with overexpressed 
pulmonary EZH2 developed lung adenocarcinomas, and long term treatment with an 
EZH2 inhibitor lead to decreased tumor burden in mice. Nearly all adenocarcinomas 
from TCGA overexpressed EZH2 compared to normal tissue, and tumors with the 
highest EZH2 expression were less likely (25% v 43%) to harbor canonical driver 
mutations in EGFR or KRAS [142], suggesting EZH2 overexpression is oncogenic on its 
own. EZH2 overexpression also affects response to treatment, as its knockdown 
enhanced cisplatin sensitivity of cisplatin-resistant cells [141]. A meta-analysis of 10 
studies, including 1695 patients, demonstrated that EZH2 overexpression was associated 
with decreased overall survival in Asian lung cancer patients and in patients with stage I 
lung adenocarcinoma [143]. That EZH2 was overexpressed in the lungs of COPD 
patients and that genes regulated by H3K27Me3 were down regulated, suggests that 
EZH2 overexpression could be one mechanism that increases lung cancer risk in COPD 
patients.  
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Among the genes associated with H3K27me3 were SLIT2, WIF1, and HPGD (Figure 
15), which are known tumor suppressors in the lung [144-147]. The repression of tumor 
suppressors is thought to be the primary mechanism by which EZH2 is itself oncogenic. 
EZH2 has previously been shown to repress SLIT2 in prostate cancer [148] and repress 
WIF1 in response to bacterial infection [149]. In addition, EPAS1 was among the genes 
decreased in tumors and with emphysema severity. EPAS1 codes for hypoxia inducible 
factor 2-alpha (HIF-2a), a suspected tumor suppressor in soft tissue sarcomas [150] and a 
key regulator of COPD [151]. RAMP2 was among the down regulated genes and has also 
been implicated as a tumor suppressor in the lung. It is frequently hyper-methylated in 
lung tumors, its expression is negatively correlated with tumor grade, and ectopic 
expression of RAMP2 can inhibit lung cancer cell growth and induce apoptosis [152]. 
Several of the genes overlapping between COPD and lung cancer and associated with 
H3K27Me3 are tumor suppressors in the lung, suggesting EZH2 overexpression 
increases lung cancer risk in COPD through H3K27Me3 regulated repression of these 
tumor suppressors.  
 
Epigenetics in smoking, COPD and lung cancer 
Epigenetic modifications are thought to mediate pulmonary effects of smoking and to 
play a role in the pathogenesis of COPD and lung cancer. The present study lends further 
credence to this hypothesis. Cigarette smoke induces distinct histone marks on histones 3 
and 4 [153] as well as the expression of multiple chromatin modification enzymes, 
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including methyltransferases and acetyltransferases, histone kinases, and ubiquitinases in 
human bronchial epithelial cells [154]. Differential methylation sites identified between 
smokers and non-smokers could also distinguish normal tissue from tumor tissue with a 
high degree of accuracy, implicating these kinds of methylation changes in both the 
response to cigarettes and pulmonary carcinogenesis. Some methylation changes were 
reversible upon smoking cessation, but some changes remained even after 22 years post 
smoking cessation [155]. This is further reflected in the observation that smoking affects 
gene expression and that some expression alterations revert to baseline post cessation and 
others remain irreversibly altered [156]. Furthermore, differentially methylated sites have 
been discovered between COPD and non-COPD smokers and the affected genes are 
involved in immune and inflammatory system pathways, the responses to stress and 
external stimuli, as well as wound healing and coagulation cascades [157]. Aberrant 
DNA methylation is a genome wide phenomenon in the small airways of COPD patients 
and regulates genes that are also part of the anti-oxidant NRF2 related pathway [24]. 
DNA methylation of genes involved in inflammatory pathways and lung development 
processes were also associated with COPD among an African-American cohort [158]. 
Lastly, some regulatory T-cell associated  immune genes are differentially expressed and 
methylated in the NSCLC tumors from COPD patients compared to the tumors from non-
COPD NSCLC patients [159]. Smoking, COPD, and lung cancer in COPD are all 
associated with various methylation changes that regulate genes involved in 
inflammation, protective pathways, and developmental processes and wound healing. 
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Clinical implications of EZH2 driven carcinogenesis in COPD 
EZH2 inhibitors have been shown to decrease tumor burden in mice and to prevent 
growth among lung cancer cells. A clinical trial for Tazemetostat, an EZH2 inhibitor, is 
currently underway and testing its efficacy against soft tissue sarcomas 
(https://clinicaltrials.gov/ct2/show/NCT02601950). If this trial shows that Tazemetostat 
is effective, its use could be expanded and tested for efficacy against lung cancer in 
COPD patients. Furthermore, depending on the safety and side effect profile of the drug, 
it could potentially be given to treat COPD as a disease modifying agent in a manner that 
could also decrease long term lung cancer risk in this patient population. EZH2 inhibitors 
are currently an area of intense research interest for treating various cancers [160].  
 
Conclusions 
In this study, I demonstrated that there are shared transcriptomic alterations associated 
with COPD, emphysema, and lung cancer. Several tumor suppressors are among the 
shared down-regulated genes, namely SLIT2, WIF1, HPGD, and RAMP2. These genes, 
and the others shared between these disease states, may be regulated by H3K27Me3, the 
effector of which, EZH2, is increased in the lungs of patients with COPD. As EZH2 is a 
known oncogene in the lung, EZH2 overexpression in the lungs of COPD patients and 
the down-regulation of genes repressed by H3K27Me3, is one mechanism that can 
increase the lung cancer risk among COPD patients.  The lungs of patients with COPD 
and the most damaged emphysematous regions share transcriptomic changes with tumors 
and may thus be primed for carcinogenesis. If EZH2 inhibitors prove effective and safe 
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therapeutics for cancer, these kinds of interventions could be used both to potentially 
modify disease progression and decrease cancer risk in COPD. 	  
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Chapter Six: Conclusions, caveats, and future directions 
In this dissertation, I leveraged genome-wide gene-expression studies of emphysema and 
lung cancer to investigate pathogenesis and carcinogenesis in COPD. The results 
presented in these studies present important   
 
Like “usual” emphysema, AATD associated emphysema is associated with decreased 
expression of genes critical to the re-epithelialization process, which helps explain why 
there is deficient repair in emphysematous lungs. While there were no obvious changes 
between the groups, the unfolded protein response appeared to play a unique role in 
AATD. The UPR affects disease progression in the livers of AATD patients, but had not 
previously been demonstrated in the lungs, and has important implications for the 
pathogenesis of emphysema in this especially susceptible population. The accepted 
mechanism of emphysema development in these patients has long been that the 
deficiency of alpha1-antitrypsin causes an imbalance between the proteinases and anti-
proteinases of the lung, which leads to excessive and irreversible degradation of the 
extracellular matrix and alveolar septal walls, i.e. emphysema. Unique activity of the 
unfolded protein response in the lungs of AATD patients suggests that misfolded AAT, 
resulting from the SERPINA1 ZZ mutation, accumulates in the cells of the lung and may 
sensitize those cells to environmental stressors, like cigarette smoke. These observations 
require further testing. Our collaborators at the University of British Columbia are in the 
process of extracting proteins from lung cores with little damage and cores with extensive 
damage to test whether classic markers of the UPR (e.g. PERK) increase with damage in 
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AATD. These findings can impact the assumptions about mechanisms of emphysema 
pathogenesis in AATD and may also impact clinical care of these patients, especially 
because replacement AAT therapy is under investigation. The UPR findings suggest that 
AAT replacement will be necessary but insufficient to treat this severe form of 
emphysema because the disease is driven by not just loss of the functional protein, but 
also by the gain of toxic function that prevents AAT from being secreted.  
 
Emphysema is a progressive disease, and the mean linear intercept (Lm) can serve as a 
surrogate of progression, but its biological relevance in non-emphysematous lungs had 
not previously been evaluated nor compared to Lm in emphysema. I wondered whether 
emphysematous transcriptomic changes would be associated with Lm in controls, and 
they were, just not in the way I originally anticipated. I discovered that genes that 
decreased with emphysema severity similarly increased with alveolar spacing (i.e. Lm) in 
non-diseased control lungs. These genes were related to TGF-beta signaling, endothelial 
cell development, epithelial cell migration, and response to nutrient levels, and may be 
part of the larger homeostatic process that maintains the non-diseased lung. Importantly, 
these findings are based on only five lungs and must be reproduced. As I demonstrated, 
these lungs were similar to those previously profiled, but this does not mean that these 
findings will hold true in larger cohorts. Overall, these findings point towards tissue 
repair processes being active in even the non-insulted lung and that their deficiency in 
emphysema may drive disease progression.  
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Finally, COPD and emphysema patients are at increased lung cancer risk, and I 
discovered that H3K27Me3 is one mechanism that could explain this. This epigenetic 
methylation mark is known to repress the expression of developmentally necessary genes, 
including tumor suppressors. Overexpression of the methyltransferase, EZH2, 
responsible for generating the histone mark, has been demonstrated to be oncogenic and 
to play a role in multiple cancer types. Genes normally repressed by EZH2 and 
H3K27Me3 were repressed in COPD and emphysema, and EZH2 was overexpressed in 
COPD. EZH2 overexpression could therefore be oncogenic in COPD patients and could 
be a good target for lung cancer interception and possibly disease modification in this 
debilitated patient population. Critically, whether H3K27Me3 is actually increased in the 
tissue of COPD patients has not been explored as part of this dissertation and should be 
investigated before any attempts to modify this epigenetic event are made. The EZH2 
inhibitor, Tazemetostat, is currently being investigated as a targeted therapy patients with 
soft tissue sarcomas with particular EZH2 alterations. If successful, this treatment could 
be extended into various cancers, including lung cancer. More importantly, if well-
tolerated, Tazemetostat could be repurposed to treat COPD patients as a preventive lung 
cancer measure that might affect COPD and emphysema pathogenesis as well.  
 
Though usual and AATD emphysema share transcriptomic signatures associated with 
tissue repair, which may be active in the normal homeostatic lung, the UPR changes in 
AATD emphysema only; successful therapeutic strategies in emphysema will need to 
account for this difference. In COPD, H3K27Me3 may play a role in both pathogenesis 
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and carcinogenesis, making it an attractive target for therapeutic interventions, but one 
that would need further augmentation in AATD.  
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